var title_f4_13_4304="Disc drusen";
var content_f4_13_4304=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F72232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F72232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Disc drusen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Don C Bienfang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_13_4304=[""].join("\n");
var outline_f4_13_4304=null;
var title_f4_13_4305="Asthma monitoring form PI";
var content_f4_13_4305=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F68404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F68404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Asthma Record - Please bring to each visit",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 574px; height: 714px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_13_4305=[""].join("\n");
var outline_f4_13_4305=null;
var title_f4_13_4306="Interactive diabetes case 8: Discordant values for A1C and home blood glucose values";
var content_f4_13_4306=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Interactive diabetes case 8: Discordant values for A1C and home blood glucose values",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/13/4306/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/13/4306/contributors\">",
"     Lloyd Axelrod, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/13/4306/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/13/4306/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/13/4306/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/13/4306/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/13/4306/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 49-year-old African American man, a computer engineer, seeks a second opinion because his physician tells him that his diabetes is uncontrolled, but the patient is sure that it is well-controlled. Five years ago, he developed polyuria, polydipsia, nocturia, and lost 23 lbs over a four-month period. A random blood glucose level was 277",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (15.3",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    The hemoglobin A1C (A1C) was 10.8 percent. The patient was treated with medical nutrition therapy and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    1000 mg twice a day with meals.",
"   </p>",
"   <p>",
"    The patient adhered to his regimen. His symptoms resolved, and he regained 18 lbs. He states that he performs self-blood glucose monitoring once or twice a day. The fasting blood glucose values are in the 110 to 125",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.1 to 6.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    range. Values before supper are 115 to 140",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.3 to 7.8",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    With treatment, the A1C level improved to the 8.9 to 9.5 range; the most recent value, nine weeks ago, was 9.1 percent.",
"   </p>",
"   <p>",
"    The patient developed distal sensory neuropathy six months after the diagnosis of diabetes. He complains of tenderness in the bottoms of his feet. He feels that he is \"walking on nerves,\" that he has \"no fat in his feet,\" and that he is \"walking on bone.\" His symptoms are alleviated by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    but are still present. He has erectile dysfunction. He also has hypertension and gastroesophageal reflux disease.",
"   </p>",
"   <p>",
"    The patient's examination reveals a blood pressure of",
"    <span class=\"nowrap\">",
"     120/70",
"    </span>",
"    in the right arm supine and",
"    <span class=\"nowrap\">",
"     140/85",
"    </span>",
"    in the right arm upright. The heart rate is 60 regular. The weight is 207 lbs, height 5' 9\", body mass index 30.6. Peripheral pulses are intact in both lower extremities. Light touch is nearly absent to the knees. Vibration sense is mildly reduced at the great toes, slightly reduced at the medial malleoli and intact at the tibial tubercles. The knee jerks and ankle jerks are absent bilaterally. In addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , the patient's medications are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    20 mg once a day,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    25 mg once a day,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    900 mg three times a day and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    81 mg once a day.",
"   </p>",
"   <p>",
"    Based on the A1C values, his physician suspects that the glucose values at home are erroneous. The physician is concerned that the patient already has distal sensory neuropathy and erectile dysfunction and may develop other complications. The physician has advised the patient to add",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/28/40391?source=see_link\">",
"     glipizide",
"    </a>",
"    5 mg before breakfast and supper to his regimen. The patient insists that the glucose readings at home are correct. He has already changed his meter to a different brand and reviewed his testing technique with a diabetes nurse educator.",
"   </p>",
"   <p>",
"    What is your assessment and plan?",
"   </p>",
"   <p>",
"    A1- You share the concern of the previous physician that the patient is at high risk of additional diabetic complications based on repeatedly elevated A1C values. You suspect that the patient is not measuring or reporting his glucoses accurately. You refer him to another diabetes nurse educator to assess the function of his glucometer and to review his testing technique. You advise him to begin",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/28/40391?source=see_link\">",
"     glipizide",
"    </a>",
"    but suggest that he start more cautiously with a dose of 2.5 mg before breakfast and supper. (See",
"    <a class=\"medical medical_answer\" href=\"UTD.htm?4/13/4306-a1?source=see_link\">",
"     \"Interactive diabetes case 8: Discordant values for A1C and home blood glucose values - A1\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A2- You suspect that the A1C level is not indicative of the patient's blood glucose values. You order yet another A1C and advise the patient to continue the current medications and not to add",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/28/40391?source=see_link\">",
"     glipizide",
"    </a>",
"    at this time. (See",
"    <a class=\"medical medical_answer\" href=\"UTD.htm?4/13/4306-a2?source=see_link\">",
"     \"Interactive diabetes case 8: Discordant values for A1C and home blood glucose values - A2\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A3- You share the concern of the previous physician that the patient is at high risk of additional diabetic complications based on repeatedly elevated A1C values. You suspect that the patient is not adhering to his diet. You refer him to a nutritionist to review his diet and to learn to count carbohydrates. (See",
"    <a class=\"medical medical_answer\" href=\"UTD.htm?4/13/4306-a3?source=see_link\">",
"     \"Interactive diabetes case 8: Discordant values for A1C and home blood glucose values - A3\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A4- You share the concern of the previous physician that the patient is at high risk of additional diabetic complications based on repeatedly elevated A1C values. You are concerned that he has post-prandial hyperglycemia, not detected by pre-meal and bedtime glucose testing. You advise him to check the blood glucose values more often, specifically before each meal, one hour after each meal, and at bedtime. (See",
"    <a class=\"medical medical_answer\" href=\"UTD.htm?4/13/4306-a4?source=see_link\">",
"     \"Interactive diabetes case 8: Discordant values for A1C and home blood glucose values - A4\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4150 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-0400165D70-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_13_4306=[""].join("\n");
var outline_f4_13_4306=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CASE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?4/13/4306-a1?source=related_link\">",
"      Interactive diabetes case 8: Discordant values for A1C and home blood glucose values - A1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?4/13/4306-a2?source=related_link\">",
"      Interactive diabetes case 8: Discordant values for A1C and home blood glucose values - A2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?4/13/4306-a3?source=related_link\">",
"      Interactive diabetes case 8: Discordant values for A1C and home blood glucose values - A3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?4/13/4306-a4?source=related_link\">",
"      Interactive diabetes case 8: Discordant values for A1C and home blood glucose values - A4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_13_4307="Darier mucosal";
var content_f4_13_4307=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Involvement of the oral mucosa in Darier's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_13_4307=[""].join("\n");
var outline_f4_13_4307=null;
var title_f4_13_4308="Ioxilan: Patient drug information";
var content_f4_13_4308=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ioxilan: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/41/31380?source=see_link\">",
"     see \"Ioxilan: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F11563664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Oxilan&reg; 300;",
"     </li>",
"     <li>",
"      Oxilan&reg; 350",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2980446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Oxilan&reg; 300;",
"     </li>",
"     <li>",
"      Oxilan&reg; 350",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10025433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700621",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is given as a shot into a vein or artery only.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691287",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used before an x-ray or an alike test.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ioxilan or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697128",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a contrast dye allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an iodine allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697341",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have sickle cell disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696097",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you by a doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12162 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.211.0.116-6A52161855-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_13_4308=[""].join("\n");
var outline_f4_13_4308=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11563664\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2980446\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025433\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025435\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025434\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025438\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025439\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025441\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025437\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025442\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025443\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/41/31380?source=related_link\">",
"      Ioxilan: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_13_4309="Amlodipine: Patient drug information";
var content_f4_13_4309=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Amlodipine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     see \"Amlodipine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/22/36199?source=see_link\">",
"     see \"Amlodipine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F133997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Norvasc&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F133998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Accel-Amlodipine;",
"     </li>",
"     <li>",
"      Amlodipine-Odan;",
"     </li>",
"     <li>",
"      Apo-Amlodipine&reg;;",
"     </li>",
"     <li>",
"      CO Amlodipine;",
"     </li>",
"     <li>",
"      Dom-Amlodipine;",
"     </li>",
"     <li>",
"      GD-Amlodipine;",
"     </li>",
"     <li>",
"      JAMP-Amlodipine;",
"     </li>",
"     <li>",
"      Manda-Amlodipine;",
"     </li>",
"     <li>",
"      Mint-Amlodipine;",
"     </li>",
"     <li>",
"      Mylan-Amlodipine;",
"     </li>",
"     <li>",
"      Norvasc&reg;;",
"     </li>",
"     <li>",
"      PHL-Amlodipine;",
"     </li>",
"     <li>",
"      PMS-Amlodipine;",
"     </li>",
"     <li>",
"      Q-Amlodipine;",
"     </li>",
"     <li>",
"      RAN&trade;-Amlodipine;",
"     </li>",
"     <li>",
"      ratio-Amlodipine;",
"     </li>",
"     <li>",
"      Riva-Amlodipine;",
"     </li>",
"     <li>",
"      Sandoz Amlodipine;",
"     </li>",
"     <li>",
"      Septa-Amlodipine;",
"     </li>",
"     <li>",
"      Teva-Amlodipine;",
"     </li>",
"     <li>",
"      ZYM-Amlodipine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691785",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701503",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to amlodipine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the arms or legs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696480",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take more often than every 24 hours unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10852 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-84F2B57B49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_13_4309=[""].join("\n");
var outline_f4_13_4309=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133997\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133998\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014546\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014545\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014550\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014551\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014553\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014548\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014549\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014554\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014555\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=related_link\">",
"      Amlodipine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/22/36199?source=related_link\">",
"      Amlodipine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_13_4310="Methadone: Patient drug information";
var content_f4_13_4310=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Methadone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     see \"Methadone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/49/22296?source=see_link\">",
"     see \"Methadone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F193997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dolophine&reg;;",
"     </li>",
"     <li>",
"      Methadone Diskets&reg;;",
"     </li>",
"     <li>",
"      Methadone Intensol&trade;;",
"     </li>",
"     <li>",
"      Methadose&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F193998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Metadol-D&trade;;",
"     </li>",
"     <li>",
"      Metadol&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700697",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause risky fast heartbeats and trouble breathing. Closely read the part in this leaflet which lists when to call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700835",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use tablets by mouth only. Do not misuse this drug and do not give as a shot. Does not mix with street drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700358",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug to treat drug addiction, you must be in a certified care program to get it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4014972",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep away from children. Accidental exposure may cause death.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691590",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease long-term pain problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat drug addiction and withdrawal.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702486",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to methadone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, bowel block, or very bad lung disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697133",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a fast heartbeat, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698594",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will watch your heartbeat with a test called an ECG.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Poor pain control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3927405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug with other strong pain drugs or if you are using a pain patch without talking to your doctor first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dispersible tablet: Drop it in fruit juice or water. Drink it when melted.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694208",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid if you cannot swallow pills. Mix liquid with",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        4",
"       </sub>",
"       cup of water before drinking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle, vein, or into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4014977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Drug addiction:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4014979",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may need to go to a clinic for your dose.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4014977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Drug addiction:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699657",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any unused drug by flushing down a toilet or sink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10849 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-60.18.131.125-10F4DE3033-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_13_4310=[""].join("\n");
var outline_f4_13_4310=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193997\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193998\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023409\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023411\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023410\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023415\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023416\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023418\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023413\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023414\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023419\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023420\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=related_link\">",
"      Methadone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/49/22296?source=related_link\">",
"      Methadone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_13_4311="Retinal vein occlusion: Epidemiology, clinical manifestations, and diagnosis";
var content_f4_13_4311=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Retinal vein occlusion: Epidemiology, clinical manifestations, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/13/4311/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/13/4311/contributors\">",
"     Douglas J Covert, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/13/4311/contributors\">",
"     Dennis P Han, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/13/4311/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/13/4311/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/13/4311/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/13/4311/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/13/4311/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H7614332\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinal vein occlusion (RVO) is an important cause of visual loss among older adults throughout the world [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/1\">",
"     1",
"    </a>",
"    ]. RVO is the second most common cause of vision loss from retinal vascular disease, following diabetic retinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, and diagnostic evaluation of RVO will be discussed here. The treatment of retinal vein occlusion, as well as general issues related to retinal artery occlusion, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38743?source=see_link\">",
"     \"Retinal vein occlusion: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3882?source=see_link\">",
"     \"Central and branch retinal artery occlusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7614340\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anatomic classification of RVO is derived from the fundoscopic appearance of the eye and includes three main groups depending on the location of venous occlusion: branch retinal vein occlusion (BRVO), central retinal vein occlusion (CRVO), and hemiretinal vein occlusion (HRVO).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BRVO occurs when a vein in the distal retinal venous system is occluded, leading to hemorrhage along the distribution of a small vessel of the retina (",
"      <a class=\"graphic graphic_picture graphicRef66642 \" href=\"UTD.htm?24/33/25104\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      CRVO occurs due to thrombus within the central retinal vein at the level of the lamina cribrosa of the optic nerve, leading to involvement of the entire retina (",
"      <a class=\"graphic graphic_picture graphicRef66675 \" href=\"UTD.htm?24/7/24689\">",
"       picture 2",
"      </a>",
"      ). The lamina cribrosa is the connective tissue &ldquo;sieve&rdquo; consisting of holes through which the nerve fibers pass from the retina to the optic nerve (",
"      <a class=\"graphic graphic_figure graphicRef78009 \" href=\"UTD.htm?33/15/34038\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      HRVO occurs when the blockage is in a vein that drains the superior or inferior hemiretina, leading to involvement of one half of the retina (",
"      <a class=\"graphic graphic_picture graphicRef78996 \" href=\"UTD.htm?13/5/13392\">",
"       picture 3",
"      </a>",
"      ). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further classification of CRVO relates to the amount of retinal capillary nonperfusion observed on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiography. (See",
"    <a class=\"local\" href=\"#H7614449\">",
"     'Fluorescein angiogram'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7614493\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7614347\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a population cohort of adults in the United States (US), the prevalence of BRVO was 0.6 percent while the prevalence of CRVO was 0.1 percent, with no significant difference between men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/3\">",
"     3",
"    </a>",
"    ]. In an Australian population, the overall prevalence of BRVO was 1.1 percent, while the prevalence of CRVO was 0.4 percent and the prevalence of HRVO was less than 0.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/4\">",
"     4",
"    </a>",
"    ]. The highest prevalence of RVO was in patients age 80 years and older (4.6 percent). BRVO was found to be asymmetrically distributed among different races with prevalences of 2.8 per 1000 in whites, 3.5 in blacks, 5.0 in Asians, and 6.0 in Hispanics [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/1\">",
"     1",
"    </a>",
"    ]. This relationship was not observed for CRVO with prevalences of 0.88 per 1000 in whites, 0.37 in blacks, 0.74 in Asians, and 1.0 in Hispanics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7614355\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are risk factors for both BRVO and CRVO [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/2,5-7\">",
"     2,5-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Diabetes",
"     </li>",
"     <li>",
"      Smoking",
"     </li>",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      Hypercoagulable state, particularly factor V Leiden and activated protein C resistance",
"     </li>",
"     <li>",
"      Glaucoma, which prevents retinal vein outflow and leads to stasis",
"     </li>",
"     <li>",
"      Retinal arteriolar abnormalities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on data from one clinic, alcohol consumption and higher levels of high-density lipoprotein cholesterol were protective factors for BRVO [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/5\">",
"     5",
"    </a>",
"    ]. Alcohol consumption and increased physical activity were protective factors for CRVO [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7614363\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many features of the pathophysiology of retinal vein occlusion (RVO) have been elucidated through autopsy and enucleation specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. Whereas branch retinal vein occlusion (BRVO) appears to be related to compression of the branch vein by retinal arterioles at the arteriovenous crossing points, central retinal vein occlusion (CRVO) is usually associated with primary thrombus formation.",
"   </p>",
"   <p>",
"    Autopsy specimens of eyes with BRVO demonstrate a relative blockage of retinal veins at arteriovenous crossings and associated sclerotic retinal arterioles [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/8\">",
"     8",
"    </a>",
"    ]. It has been hypothesized that an inflexible, sclerotic arteriole deforms the relatively distensible veins that are contained in an inelastic arteriovenous sheath. Several studies have suggested that BRVO is correlated with the relative anteroposterior position of the retinal artery and vein [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. In one series of 106 eyes with BRVO, for example, all cases showed the site of the retinal vein obstruction was at an arteriovenous crossing, and in 99 percent of eyes the artery was anterior to the vein [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/9\">",
"     9",
"    </a>",
"    ]. In contrast, the artery was anterior to the vein only 60 percent of the time in subjects without BRVO [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a histopathologic study of eyes in patients with CRVO, thrombus consisting of fibrin and platelets in the central retinal vein was observed in those with recent onset of CRVO [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/12\">",
"     12",
"    </a>",
"    ]. Recanalization of the thrombus was noted in eyes examined after CRVO had been present for more than two weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7614371\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with branch retinal vein occlusion (BRVO) are asymptomatic and are diagnosed on routine ophthalmologic examination. Alternatively, patients may describe a scotoma or visual field deficit with blurred or gray vision corresponding to the area of retinal vein occlusion. Patients with BRVO involving the macula typically complain of blurred central vision.",
"   </p>",
"   <p>",
"    Patients with central retinal vein occlusion (CRVO) usually complain of painless acute onset of blurred vision in one eye. CRVO is seldom asymptomatic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26888?source=see_link\">",
"     \"Approach to the adult with acute persistent visual loss\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10666?source=see_link\">",
"     \"Amaurosis fugax (transient monocular or binocular visual loss)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who present with chronic RVO may exhibit additional findings. Neovascularization of the iris",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neovascularization of the anterior chamber angle can lead to the development of neovascular glaucoma. In addition to decreased vision, these patients may complain of a red, painful eye secondary to elevated intraocular pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17607?source=see_link\">",
"     \"Evaluation of the red eye\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7614380\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7614388\">",
"    <span class=\"h2\">",
"     Visual acuity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether visual loss progresses depends largely on the type and location of RVO [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with non-macular branch retinal vein occlusion (BRVO) are commonly asymptomatic and usually do not experience loss of visual acuity. Patients with macular edema from BRVO may experience spontaneous vision improvement in the first three months after onset of symptoms. After three months, the likelihood of spontaneous improvement in visual acuity diminishes. Three-year visual acuity outcomes in untreated eyes with BRVO-associated macular edema and visual acuity of",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    or worse at three months is as follows: 34 percent with visual acuity of",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    or better, 23 percent with visual acuity of",
"    <span class=\"nowrap\">",
"     20/200",
"    </span>",
"    or worse, and an average visual acuity of",
"    <span class=\"nowrap\">",
"     20/70",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with central retinal vein occlusion (CRVO) have worse outcomes, with final visual acuity dependent upon visual acuity at presentation. The Central Retinal Vein Occlusion Study followed 725 patients with CRVO over three years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/14\">",
"     14",
"    </a>",
"    ]. Two-thirds of patients who presented with visual acuity &ge;",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    maintained visual acuity in the same range, and only 10 percent had worsening of visual acuity to &lt;",
"    <span class=\"nowrap\">",
"     20/200.",
"    </span>",
"    Among patients who presented with visual acuity",
"    <span class=\"nowrap\">",
"     20/50",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     20/200,",
"    </span>",
"    nearly half maintained visual acuity in the same range and one-third progressed to a visual acuity &lt;",
"    <span class=\"nowrap\">",
"     20/200.",
"    </span>",
"    Only 20 percent of patients with initial visual acuity &lt;",
"    <span class=\"nowrap\">",
"     20/200",
"    </span>",
"    had some improvement in vision. Patients with ischemic CRVO are at high risk for poor visual acuity at initial presentation and over the long-term, compared to those with non-ischemic CRVO [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7614396\">",
"    <span class=\"h2\">",
"     Ocular neovascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neovascularization of the iris (NVI), anterior chamber angle (NVA), and retina are common complications of both CRVO and BRVO, although",
"    <span class=\"nowrap\">",
"     NVI/NVA",
"    </span>",
"    occur more commonly in CRVO. In the Central Retinal Vein Occlusion Study,",
"    <span class=\"nowrap\">",
"     NVI/NVA",
"    </span>",
"    developed in 16 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/14\">",
"     14",
"    </a>",
"    ]. The strongest predictors of",
"    <span class=\"nowrap\">",
"     NVI/NVA",
"    </span>",
"    were visual acuity at diagnosis and the area of nonperfusion by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiogram. For eyes initially categorized as nonperfused or indeterminate, 35 percent developed",
"    <span class=\"nowrap\">",
"     NVI/NVA,",
"    </span>",
"    compared with 10 percent of those initially categorized as perfused [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neovascularization of the retina can lead to vitreous hemorrhage, traction retinal detachment, and neovascular glaucoma. Vitreous hemorrhage may produce visual disturbances such as severe floaters and intermittent visual obscurations. Development of neovascular glaucoma may result in significant ocular morbidity, such as pain, chronic ocular redness, unremitting intraocular pressure elevation, and profound visual loss that is often unresponsive to anti-glaucoma drops or surgery. Iris neovascularization or anterior chamber angle neovascularization are considered harbingers of neovascular glaucoma, and are most likely to occur in eyes with ischemic CRVO. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/41/36504?source=see_link\">",
"     \"Retinal detachment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9063?source=see_link&amp;anchor=H3#H3\">",
"     \"Angle-closure glaucoma\", section on 'Types of angle-closure glaucoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26888?source=see_link&amp;anchor=H9#H9\">",
"     \"Approach to the adult with acute persistent visual loss\", section on 'Vitreous hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7614404\">",
"    <span class=\"h2\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;It remains unclear if RVO is associated with cardiovascular disease. A retrospective cohort study of 4500 patients with RVO and 13500 control patients suggested no increased risk of myocardial infarction in patients with RVO but a higher risk of stroke (RR 1.7, 95% CI 1.3-2.3) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/17\">",
"     17",
"    </a>",
"    ]. In one large population-based study (age 43 to 86 years), RVO was not associated with cardiovascular-related mortality or cerebrovascular-related mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/18\">",
"     18",
"    </a>",
"    ]. However, in persons 70 years or younger, baseline RVO was associated with higher cardiovascular mortality after adjusting for known risk factors and comorbidities (HR 2.5, 95% CI 1.2-5.2) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7614411\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of retinal vein occlusion (RVO), like other retinal diseases, begins with the history and a complete ophthalmologic examination. Other testing such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiography and coherence tomography may be performed to confirm the diagnosis and follow disease progression or response to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7614419\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the diagnosis is based primarily on eye examination and other diagnostic studies, a history is important for documenting the patient's symptomatic visual loss and presence of other comorbid conditions.",
"   </p>",
"   <p>",
"    The history should include the timing and severity of visual loss. Patients with branch retinal vein occlusion (BRVO) usually have no complaints, with occasional focal blurriness. Patients with central retinal vein occlusion (CRVO) often report sudden, unilateral loss of vision.",
"   </p>",
"   <p>",
"    Associated symptoms including pain or systemic symptoms are unusual in RVO. A history of other comorbid conditions should be documented, particularly cardiovascular risk factors that may predispose to RVO. (See",
"    <a class=\"local\" href=\"#H7614355\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7614426\">",
"    <span class=\"h2\">",
"     Eye examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The eye examination includes evaluation of extraocular motility, intraocular pressure, pupillary function, and the external and internal structures of the eye. This also includes confrontational visual fields, slit lamp examination, testing for visual acuity, and a dilated fundoscopic examination.",
"   </p>",
"   <p>",
"    Findings in patients with BRVO are largely normal, except for the fundoscopic examination and testing of visual acuity.",
"   </p>",
"   <p>",
"    In patients with CRVO, pupillary examination can be normal but typically demonstrates ipsilateral relative afferent pupillary defect in cases of nonperfused CRVO. Confrontational visual field deficits are variable. Anterior slit lamp examination is usually normal in the acute phase. The fundoscopic examination shows typical findings. Intraocular pressure is unaffected in the acute phase, prior to development of neovascularization of the angle (NVA).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7614433\">",
"    <span class=\"h3\">",
"     Visual acuity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visual acuity should be documented at each visit to assess RVO progression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    response to treatment. Assessment of visual acuity is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2329?source=see_link&amp;anchor=H18#H18\">",
"     \"Visual impairment in adults: Refractive disorders and presbyopia\", section on 'Screening and diagnostic tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7614441\">",
"    <span class=\"h3\">",
"     Fundus examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In both BRVO and CRVO, the fundus examination should reveal retinal hemorrhage and edema, as well as dilated retinal veins.",
"   </p>",
"   <p>",
"    In patients with BRVO, the retinal hemorrhages are focal or wedge-shaped, with the apex situated at the offending arteriovenous crossing (",
"    <a class=\"graphic graphic_picture graphicRef54488 \" href=\"UTD.htm?20/11/20656\">",
"     picture 4",
"    </a>",
"    ). Variable amounts of retinal edema are present within this region. The distribution corresponds to the area that is served by the affected retinal vein. There may also be venous dilatation radiating from the arteriovenous crossing (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53326 \" href=\"UTD.htm?29/48/30467\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In patients with CRVO, the retinal hemorrhage is scattered and diffuse, with optic disc edema in some patients. The classic appearance of CRVO has been termed \"blood and thunder\" fundus. Dilated and tortuous veins are visualized. All four quadrants have intraretinal hemorrhages (",
"    <a class=\"graphic graphic_picture graphicRef66675 \" href=\"UTD.htm?24/7/24689\">",
"     picture 2",
"    </a>",
"    ). Cotton wool spots are observed in approximately half of patients with CRVO [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/19\">",
"     19",
"    </a>",
"    ]. The arterioles may be attenuated, indicating generalized arteriosclerotic disease.",
"   </p>",
"   <p>",
"    The amount of capillary nonperfusion cannot be reliably determined on fundus examination alone. Thus,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiography is often required. It is our practice to obtain fluorescein angiography on all patients with suspected RVO.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7614449\">",
"    <span class=\"h2\">",
"     Fluorescein angiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the history and eye examination findings are suggestive of RVO, a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiogram should be performed to confirm the diagnosis and assess the degree of retinal nonperfusion. In the acute phase, the fluorescein angiogram may reveal delayed venous filling, staining of affected retinal veins, and angiographic macular leakage.",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiogram also allows quantification of the surface area of capillary nonperfusion. The Central Retinal Vein Occlusion Study Group established a perfusion classification scheme, based on disk area, that is now commonly used [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/19\">",
"     19",
"    </a>",
"    ]. A disk area represents the surface area of the optic nerve head. In this scheme, cases with &lt;10 disk areas of capillary nonperfusion are classified as \"perfused CRVO,\" and cases with &ge;10 disk areas of capillary nonperfusion are classified as \"nonperfused CRVO.\" Cases of CRVO where the extent of capillary nonperfusion cannot be determined due to extensive intraretinal hemorrhage are classified as \"indeterminant\" [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/2\">",
"     2",
"    </a>",
"    ]. The amount and location of capillary nonperfusion in BRVOs is helpful to predict visual acuity and neovascularization risk.",
"   </p>",
"   <p>",
"    In the chronic phase of RVO, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiogram may provide additional findings. It helps document the presence of collateral vessels, which divert blood from the retinal circulation to the choroidal circulation. These vessels are larger caliber than neovascularization and do not leak in late frames of the angiogram. In contrast, neovascularization would appear to be fine fronds of vessels that leak profusely in late frames.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7614456\">",
"    <span class=\"h2\">",
"     Optical coherence tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macular optical coherence tomography (OCT) allows high-resolution cross sectional imaging of the retina. Its main use in RVO is in quantifying retinal thickening from intraretinal fluid in cases of macular edema (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53309 \" href=\"UTD.htm?17/41/18065\">",
"     image 2",
"    </a>",
"    ). OCT can then be used on follow-up visits to assess the progression of RVO or response to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7614463\">",
"    <span class=\"h2\">",
"     Additional testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little consensus to guide which ancillary tests should be performed in patients with RVO. In the majority of patients, additional laboratory work-up yields little helpful information. However, detecting and treating those patients with undiagnosed risk factors may help to prevent further episodes or worsening of RVO.",
"   </p>",
"   <p>",
"    Patients should be screened for cardiovascular risk factors. We suggest that screening should include a fasting glucose or hemoglobin A1C and a fasting lipid panel.",
"   </p>",
"   <p>",
"    Contributing thrombotic factors should be investigated in patients with a previous history of thrombotic events. We also evaluate younger patients (age &lt;50 years) without known risk factors for RVO, although there is no available strong evidence in this regard. (See",
"    <a class=\"local\" href=\"#H7614355\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    A significant past medical history or family history of thrombotic events should prompt a hypercoagulable workup. Two meta-analyses find an association for RVO and factor V Leiden, homocysteine, and anticardiolipin antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/7,20\">",
"     7,20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One meta-analysis evaluated the prevalence of factor V Leiden and activated protein C resistance in patients with RVO [",
"      <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/7\">",
"       7",
"      </a>",
"      ]. They found a modest association with factor V Leiden (OR 1.7, 95% CI 1.2-2.3) and no association with activated protein C.",
"     </li>",
"     <li>",
"      In another meta-analysis evaluating several other thrombophilic factors, hyperhomocysteinemia (OR 8.9, 95% CI 5.7-13.7) and anticardiolipin antibody 3.9 (95% CI 2.3-6.7) were the only factors associated with an increased risk of RVO [",
"      <a class=\"abstract\" href=\"UTD.htm?4/13/4311/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on these findings, we suggest testing for factor V Leiden mutation, homocysteine, and anticardiolipin antibody in patients with a history suggesting a hypercoagulable state. In patients determined to have a high-risk hypercoagulable state, anticoagulation guided by a hematologist should be considered although evidence to support this practice is lacking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7614470\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retinal vein occlusion (RVO) is an important cause of visual loss worldwide. (See",
"      <a class=\"local\" href=\"#H7614493\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The classification of RVO is based on the site of retinal vein involvement. Branch retinal vein occlusion (BRVO) occurs when a vein in the distal retinal venous system is occluded, leading to blockage of a relatively small portion of the retina. Central retinal vein occlusion (CRVO) occurs due to thrombus within the central retinal vein, leading to involvement of the entire retina. (See",
"      <a class=\"local\" href=\"#H7614340\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with BRVO may be asymptomatic and detected on routine eye examination. Occasionally, patients with BRVO will describe a visual field deficit with blurred or gray vision, corresponding to the area of retinal vein occlusion. If the macula is affected, patients with BRVO may complain of blurred vision. Patients with CRVO usually complain of painless, acute onset of blurred vision. (See",
"      <a class=\"local\" href=\"#H7614371\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation of RVO includes a history and a complete ophthalmic examination. Important components of the ophthalmic examination include visual acuity and dilated fundus examination looking for hemorrhage, edema, and dilatation of the retinal veins. Other testing such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      angiogram and coherence tomography may be performed to confirm the diagnosis and follow disease progression or response to treatment. (See",
"      <a class=\"local\" href=\"#H7614411\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4311/abstract/1\">",
"      Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010; 117:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4311/abstract/2\">",
"      Cugati S, Wang JJ, Rochtchina E, Mitchell P. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol 2006; 124:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4311/abstract/3\">",
"      Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000; 98:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4311/abstract/4\">",
"      Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 1996; 114:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4311/abstract/5\">",
"      Risk factors for branch retinal vein occlusion. The Eye Disease Case-control Study Group. Am J Ophthalmol 1993; 116:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4311/abstract/6\">",
"      Risk factors for central retinal vein occlusion. The Eye Disease Case-Control Study Group. Arch Ophthalmol 1996; 114:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4311/abstract/7\">",
"      Rehak M, Rehak J, M&uuml;ller M, et al. The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis. Thromb Haemost 2008; 99:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4311/abstract/8\">",
"      Bowers DK, Finkelstein D, Wolff SM, Green WR. Branch retinal vein occlusion. A clinicopathologic case report. Retina 1987; 7:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4311/abstract/9\">",
"      Zhao J, Sastry SM, Sperduto RD, et al. Arteriovenous crossing patterns in branch retinal vein occlusion. The Eye Disease Case-Control Study Group. Ophthalmology 1993; 100:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4311/abstract/10\">",
"      Weinberg D, Dodwell DG, Fern SA. Anatomy of arteriovenous crossings in branch retinal vein occlusion. Am J Ophthalmol 1990; 109:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4311/abstract/11\">",
"      Duker JS, Brown GC. Anterior location of the crossing artery in branch retinal vein obstruction. Arch Ophthalmol 1989; 107:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4311/abstract/12\">",
"      Green WR, Chan CC, Hutchins GM, Terry JM. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc 1981; 79:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4311/abstract/13\">",
"      Finkelstein D. Ischemic macular edema. Recognition and favorable natural history in branch vein occlusion. Arch Ophthalmol 1992; 110:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4311/abstract/14\">",
"      Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. Arch Ophthalmol 1997; 115:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4311/abstract/15\">",
"      Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol 1984; 98:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4311/abstract/16\">",
"      Hayreh SS, Podhajsky PA, Zimmerman MB. Natural history of visual outcome in central retinal vein occlusion. Ophthalmology 2011; 118:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4311/abstract/17\">",
"      Werther W, Chu L, Holekamp N, et al. Myocardial infarction and cerebrovascular accident in patients with retinal vein occlusion. Arch Ophthalmol 2011; 129:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4311/abstract/18\">",
"      Cugati S, Wang JJ, Knudtson MD, et al. Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts. Ophthalmology 2007; 114:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4311/abstract/19\">",
"      Baseline and early natural history report. The Central Vein Occlusion Study. Arch Ophthalmol 1993; 111:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4311/abstract/20\">",
"      Janssen MC, den Heijer M, Cruysberg JR, et al. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thromb Haemost 2005; 93:1021.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15264 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-1A4E1675F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_13_4311=[""].join("\n");
var outline_f4_13_4311=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7614470\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7614332\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7614340\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7614493\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7614347\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7614355\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7614363\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7614371\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7614380\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7614388\">",
"      Visual acuity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7614396\">",
"      Ocular neovascularization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7614404\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7614411\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7614419\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7614426\">",
"      Eye examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7614433\">",
"      - Visual acuity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7614441\">",
"      - Fundus examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7614449\">",
"      Fluorescein angiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7614456\">",
"      Optical coherence tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7614463\">",
"      Additional testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7614470\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/15264\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/15264|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/48/30467\" title=\"diagnostic image 1\">",
"      Dilated vein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/41/18065\" title=\"diagnostic image 2\">",
"      Optical coherence tomograph",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/15264|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/15/34038\" title=\"figure 1\">",
"      Types retinal vein occl",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/15264|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/33/25104\" title=\"picture 1\">",
"      Occl superotemporal branch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/7/24689\" title=\"picture 2\">",
"      Central retinal vein occ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/5/13392\" title=\"picture 3\">",
"      Hemiretinal vein occlusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/11/20656\" title=\"picture 4\">",
"      Wedge two",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10666?source=related_link\">",
"      Amaurosis fugax (transient monocular or binocular visual loss)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9063?source=related_link\">",
"      Angle-closure glaucoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26888?source=related_link\">",
"      Approach to the adult with acute persistent visual loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3882?source=related_link\">",
"      Central and branch retinal artery occlusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17607?source=related_link\">",
"      Evaluation of the red eye",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/41/36504?source=related_link\">",
"      Retinal detachment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38743?source=related_link\">",
"      Retinal vein occlusion: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2329?source=related_link\">",
"      Visual impairment in adults: Refractive disorders and presbyopia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_13_4312="Normal liver bx with Rx PBC";
var content_f4_13_4312=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normalization of liver biopsy after methotrexate for primary biliary cirrhosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 291px; height: 472px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sequential liver biopsies in patient with primary biliary cirrhosis. Top panel: Liver bipsy performed five years after the diagnosis of PBC and one year after treatment with colchicine (0.6 mg BID). The portal triads are greatly enlarged, somewhat edematous and infiltrated with mononuclear inflammatory cells. There is bridging of adjacent triads, and early nodule formation is evident. The biopsy is that of stage III to IV PBC. Bottom panel: Repeat liver biopsy after six years on methotrexate. The biopsy is normal except for a few portal triads that are minimally enlarged and infiltrated with mononuclear cells. There are no longer any features of PBC. The patient is asymptomatic and liver enzymes are normal. Masson trichrome, x 94.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission from: Kaplan M, DeLellis R, Wolfe H. Ann Intern Med 1997; 126:682.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_13_4312=[""].join("\n");
var outline_f4_13_4312=null;
var title_f4_13_4313="Obstetrical management of pregnancies complicated by gestational diabetes mellitus";
var content_f4_13_4313=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Obstetrical management of pregnancies complicated by gestational diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/13/4313/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/13/4313/contributors\">",
"     Aaron B Caughey, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/13/4313/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/13/4313/contributors\">",
"     Michael F Greene, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/13/4313/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/13/4313/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/13/4313/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstetrical challenges in caring for pregnant women with gestational diabetes mellitus (GDM) include knowledge of the maternal and fetal risks related to the disorder, antepartum maternal and fetal monitoring, use of obstetrical ultrasound to monitor fetal growth and well-being, decisions about timing and route of delivery, intrapartum obstetric and glycemic management, and postpartum assessment.",
"   </p>",
"   <p>",
"    This topic will address issues related to obstetric management of women diagnosed with GDM after screening at 24 to 28 weeks of gestation. Screening, diagnosis, and glycemic management of women with gestational diabetes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9210?source=see_link\">",
"     \"Screening and diagnosis of diabetes mellitus during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37866?source=see_link\">",
"     \"Medical management and follow-up of gestational diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Obstetrical and medical management of pregnant women with type 1 and type 2 diabetes mellitus are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35818?source=see_link\">",
"     \"Obstetrical management of pregnancy complicated by pregestational diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20794?source=see_link\">",
"     \"Medical management of type 1 and type 2 diabetes mellitus in pregnant women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=see_link\">",
"     \"Pregnancy risks in women with type 1 and type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42487?source=see_link\">",
"     \"Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FOCUS OF PRENATAL CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to routine pregnancy issues, the prenatal care of women with GDM focuses upon identifying and managing conditions that are more common among women with glucose impairment. Maintaining good glycemic control is the key intervention for reducing the frequency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severity of these conditions. In contrast to women with pregestational diabetes, women with GDM typically do not have overt vasculopathy or an increased risk of infants with congenital malformations.",
"   </p>",
"   <p>",
"    Conditions more common in GDM include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Macrosomia",
"      </strong>",
"      &mdash; Randomized trials have consistently demonstrated that maternal hyperglycemia significantly increases a woman's chances of having a macrosomic or large for gestational age (LGA) infant [",
"      <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/1-4\">",
"       1-4",
"      </a>",
"      ], and excessive maternal weight gain (&gt;40 lbs [18 kg]) doubles the risk [",
"      <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/5\">",
"       5",
"      </a>",
"      ]. Macrosomia, in turn, is associated with an increased risk of operative delivery (cesarean or instrumental vaginal) and adverse neonatal outcomes, such as shoulder dystocia, brachial plexus injury, and clavicular fracture [",
"      <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/6-11\">",
"       6-11",
"      </a>",
"      ]. Truncal asymmetry (disproportion in the ratio of the size of the shoulder or abdomen-to-head) in infants of diabetic mothers also appears to increase the risk [",
"      <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/1/16408?source=see_link\">",
"       \"Timing and route of delivery in pregnancies at risk of shoulder dystocia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41752?source=see_link\">",
"       \"Intrapartum management and outcome of shoulder dystocia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44809?source=see_link\">",
"       \"Infant of a diabetic mother\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Preeclampsia",
"      </strong>",
"      &mdash; Women with GDM are at higher risk of developing preeclampsia than women without GDM, possibly due, at least in part, to insulin resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/14-19\">",
"       14-19",
"      </a>",
"      ]. A significant association (OR 1.3-3.1) between midtrimester insulin resistance and development of preeclampsia has been reported in several studies, even in the absence of GDM [",
"      <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/19-22\">",
"       19-22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"       \"Preeclampsia: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=see_link\">",
"       \"Preeclampsia: Management and prognosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41609?source=see_link\">",
"       \"Prevention of preeclampsia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hydramnios",
"      </strong>",
"      &mdash; Although hydramnios is more common in women with GDM, it does not appear to be associated with a significant increase in perinatal morbidity or mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Stillbirth",
"      </strong>",
"      &mdash; Fetuses of women with GDM appear to be at higher risk of intrauterine demise [",
"      <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/25-27\">",
"       25-27",
"      </a>",
"      ]. This risk seems to be related primarily to poor glycemic control [",
"      <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Neonatal morbidity",
"      </strong>",
"      &mdash; Neonates of pregnancies complicated by GDM are at increased risk of hypoglycemia, hyperbilirubinemia, hypocalcemia, erythremia, and respiratory distress syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44809?source=see_link\">",
"       \"Infant of a diabetic mother\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risks associated with GDM extend beyond the pregnancy and neonatal period. GDM may affect the offspring's risk of becoming obese or developing impaired glucose tolerance or metabolic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. GDM is also a marker for subsequent maternal development of type 2 diabetes, including diabetes-associated vascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF PREGNANCY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Glucose monitoring and control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glycemic control is the cornerstone of management of any diabetic pregnancy. Glucose monitoring, medical nutritional therapy, exercise, and the use of insulin and anti-hyperglycemic agents are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37866?source=see_link\">",
"     \"Medical management and follow-up of gestational diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Antenatal fetal testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The literature supporting antenatal fetal testing in pregnancies complicated by GDM consists primarily of observational series that report no or rare fetal losses among a group of pregnancies followed by various testing regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. There are no randomized trials evaluating obstetrical management of women with GDM specifically, and findings from the small number of cohort and case-control studies are inconclusive.",
"   </p>",
"   <p>",
"    The practice pattern that has evolved is to base use of fetal testing on (1) the severity of GDM (ie, whether euglycemia is achieved and whether it is achieved by",
"    <span class=\"nowrap\">",
"     nutrition/exercise",
"    </span>",
"    achieve or by pharmacologic therapy) and (2) the presence of other risk factors for adverse pregnancy outcome (eg, advanced maternal age, past history of stillbirth, presence of comorbidities such as chronic hypertension).",
"   </p>",
"   <p>",
"    The timing for initiating testing in the third trimester, the frequency of testing, and the actual tests utilized (eg, nonstress test, biophysical profile score, contraction stress test) vary by institution and practice setting.",
"   </p>",
"   <p>",
"    Expert opinion generally recommends that women who require insulin or an oral antihyperglycemic agent (ie, class A2 GDM) to maintain euglycemia are managed the same way as women with pregestational diabetes or other conditions placing the pregnancy at increased risk of adverse outcome. These women typically undergo antenatal testing twice weekly, usually initiated at about 32 weeks of gestation. Since women who are euglycemic with nutritional therapy alone (ie, class A1 GDM) and who have no other pregnancy complications (eg, no macrosomia, preeclampsia, growth restriction, polyhydramnios or oligohydramnios) do not appear to be at increased risk of stillbirth; therefore, antepartum fetal surveillance with nonstress testing or biophysical profile scoring is not required for maternal A1 GDM alone [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/35,38\">",
"     35,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30121?source=see_link\">",
"     \"Overview of fetal assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Assessment of fetal growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of accelerated fetal growth may be useful to identify [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mother-fetal pairs who may benefit from induction of labor before the fetus grows too large",
"     </li>",
"     <li>",
"      Mother-fetal pairs who may benefit from scheduled cesarean delivery when fetal size exceeds some threshold",
"     </li>",
"     <li>",
"      Women whose glycemic control may not be optimal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unfortunately, there is no method of fetal growth assessment that performs well; all current methods are neither sensitive nor specific, especially for identifying the large for gestational age fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. One review of pregnant women with diabetes treated with insulin found that the sonographically estimated fetal weight had to be &ge;4800 grams for there to be at least a 50 percent chance the infant's birthweight would be &ge;4500 grams [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/45\">",
"     45",
"    </a>",
"    ]. Studies in nondiabetic pregnancies report similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/46\">",
"     46",
"    </a>",
"    ]. Investigators have tried to find a more sensitive modality to estimate fetal weight, but there is little evidence that these experimental modalities can improve on existing two-dimensional ultrasound technology [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. The diagnosis of fetal macrosomia is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31337?source=see_link&amp;anchor=H5#H5\">",
"     \"Fetal macrosomia\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31337?source=see_link&amp;anchor=H22#H22\">",
"     \"Fetal macrosomia\", section on 'Diabetic mother'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In view of these limitations, a wide practice spectrum has evolved, ranging from a single ultrasound at 36 weeks of gestation to assess the potential for macrosomia to frequent ultrasounds to monitor fetal growth (eg, at 28, 32, and 36 weeks of gestation) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/51\">",
"     51",
"    </a>",
"    ]. Similar to the situation with antenatal testing, some providers do not monitor fetal growth sonographically in euglycemic women with A1 GDM (medical nutritional therapy alone) because of concern that false-positive findings will lead to iatrogenic complications. As an example, one study reported an increase in cesarean delivery among women who had a third trimester ultrasound examination, even after controlling for birthweight [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Timing of delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the key issues of the management of women with GDM is whether to induce labor, and if so, when? The major potential benefits of induction are avoidance of late stillbirth and avoidance of delivery-related complications of continued fetal growth, such as shoulder dystocia or cesarean delivery. The potential disadvantages include the risks of induction (eg, cesarean delivery if the induction fails, tachysystole, iatrogenic prematurity). The optimal timing of delivery in GDM has not been evaluated in well-designed trials; the available data [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/53-57\">",
"     53-57",
"    </a>",
"    ] are inadequate to allow an evidence-based recommendation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=see_link\">",
"     \"Principles of labor induction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The only randomized trial evaluating timing of delivery in diabetic pregnancies included 200 women with uncomplicated insulin-requiring diabetes (13 pregestational, 187 gestational) and appropriately grown fetuses [",
"      <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/53\">",
"       53",
"      </a>",
"      ]. Elective induction during the 38th week of gestation was advantageous compared with expectant management because of a lower prevalence of LGA infants (10 versus 23 percent with expectant management), fewer cases of shoulder dystocia (0 versus 3 percent with expectant management), and a lower rate of cesarean delivery (25 versus 31 percent with expectant management). The expectantly managed group delivered, on average, a week later than the elective induction group and 50 percent of women in the expectant management group ultimately required induction for obstetrical indications.",
"     </li>",
"     <li>",
"      A cohort study of induction of labor in women with GDM treated with insulin found the group electively induced at 38 to 39 weeks of gestation had a significantly lower rate of shoulder dystocia than the expectantly managed group (1.4 versus 10 percent), and no increased risk of cesarean delivery [",
"      <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other evidence that supports preventive labor induction comes from a study that compared birth outcomes resulting from the active management of risk in pregnancy at term (AMOR-IPAT) to outcomes that resulted from standard management [",
"      <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/59\">",
"       59",
"      </a>",
"      ]. In the AMOR-IPAT protocol, women with GDM were induced eight days before their due date. In this retrospective cohort study, the actively managed group had a higher induction rate (63 versus 25.7 percent) than the standard care group, and a lower cesarean delivery rate (4 versus 16.7 percent). Findings were similar for both nulliparous and multiparous subgroups. The median gestational ages at delivery for the electively induced and standard care groups were 38.9 and 40.1 weeks, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a pilot randomized trial of this concept, the AMOR-IPAT exposed group had a similar cesarean delivery rate as the usual care group (10.3 versus 14.9 percent), but a significantly lower rate of neonatal intensive care unit admission (1.5 versus 6.7 percent), a significantly higher rate of uncomplicated vaginal birth (73.5 versus 62.8 percent), and a significantly lower mean adverse outcome index score [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/60\">",
"     60",
"    </a>",
"    ]. The median gestational ages at delivery for the electively induced and standard care groups were 39.1 and 40.0 weeks, respectively.",
"   </p>",
"   <p>",
"    Given these and other data [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/38\">",
"     38",
"    </a>",
"    ], the practice pattern that has evolved in many institutions is to manage pregnancies of women who remain euglycemic with diet and exercise alone by beginning a discussion about the possibility of induction of labor when the woman reaches her estimated date of delivery,",
"    <span class=\"nowrap\">",
"     40",
"     <sup>",
"      0/7",
"     </sup>",
"    </span>",
"    weeks of gestation, and recommending elective induction when she reaches",
"    <span class=\"nowrap\">",
"     41",
"     <sup>",
"      0/7",
"     </sup>",
"    </span>",
"    weeks of gestation. Induction of labor at this gestational age reduces the risks associated with postterm pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16535?source=see_link\">",
"     \"Postterm pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest that women with GDM whose glucose levels are medically managed with insulin or oral agents undergo induction of labor at 39 weeks of gestation. Data from a retrospective cohort study of women with GDM indicate that the infant mortality rate at 39 weeks",
"    <span class=\"nowrap\">",
"     (8.7/10,000)",
"    </span>",
"    is statistically lower than the risk of stillbirth plus infant mortality with expectant management over an additional week",
"    <span class=\"nowrap\">",
"     (15.2/10,000)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/61\">",
"     61",
"    </a>",
"    ]. Early term delivery is not indicated in uncomplicated pregnancies with well controlled glucose levels [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/62\">",
"     62",
"    </a>",
"    ]. If a concomitant medical condition (eg, hypertension) is present or glycemic control is suboptimal, we suggest induction of labor at 38 weeks of gestation after confirmation of fetal lung maturity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42919?source=see_link\">",
"     \"Assessment of fetal lung maturity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Scheduled cesarean delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;When scheduled cesarean delivery should be performed to reduce the risk of birth trauma from shoulder dystocia is controversial. It has been estimated that in nondiabetic pregnancies with an estimated fetal weight of &ge;4500 grams, 443 cesareans would need to be performed to prevent one permanent brachial plexus injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/44\">",
"     44",
"    </a>",
"    ]. Whether this trade-off justifies the increased risks of cesarean delivery is unclear. The American College of Obstetricians and Gynecologists (ACOG) practice bulletin on macrosomia suggests that, in patients without diabetes, an elective cesarean delivery is reasonable when the estimated fetal weight &ge;5000 grams [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. However, ACOG is less clear about what to do in the setting of both macrosomia and diabetes, and states scheduled cesarean \"may be considered\" in women with diabetes and estimated fetal weight &ge;4500 grams.",
"   </p>",
"   <p>",
"    Theoretically, if the fetus of a woman with diabetes has a risk of shoulder dystocia equivalent to that of a fetus 250 g heavier of a nondiabetic woman [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/13\">",
"     13",
"    </a>",
"    ], then it seems reasonable to offer scheduled cesarean to women with GDM with estimated fetal weight &ge;4750 grams. However, it should be remembered that sonographically estimated fetal weight &ge;4800 grams is associated with only about a 50 percent chance that the infant's birthweight will be &ge;4500 grams, thus many scheduled cesareans will result in delivery of infants &lt;4500 grams and not at high risk of shoulder dystocia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When counseling patients, key issues to address include: (1) the difficulty in accurately predicting birthweight by any method; (2) the risks of a cesarean delivery in the current pregnancy, and (3) the risks of a prior cesarean delivery on management and outcome of future pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21449?source=see_link\">",
"     \"Cesarean delivery: Postoperative issues\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37862?source=see_link\">",
"     \"Repeat cesarean delivery\"",
"    </a>",
"    .) If a woman with estimated fetal weight &ge;4500 grams decides to undergo a trial of labor, we follow labor progress closely and perform an operative vaginal delivery only if the fetal vertex has descended normally in the second stage of labor because instrumental delivery is associated with a higher risk of shoulder dystocia and brachial plexus injury, and the risk is higher with the use of vacuum than with forceps [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/1/16408?source=see_link&amp;anchor=H14#H14\">",
"     \"Timing and route of delivery in pregnancies at risk of shoulder dystocia\", section on 'Timing and route of delivery in at risk pregnancies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Labor and delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal hyperglycemia should be avoided during labor to reduce the risk of fetal acidosis and neonatal hypoglycemia. The risk of adverse neonatal metabolic outcomes (hypoglycemia, hyperbilirubinemia, hypocalcemia, erythremia) is related to both antepartum and intrapartum maternal hyperglycemia and appears to increase with the degree of maternal hyperglycemia.",
"   </p>",
"   <p>",
"    Insulin requirements usually decrease during labor, as the work of labor, particularly uterine contractions, requires energy and oral caloric intake is typically reduced. Women with GDM who were euglycemic without use of insulin or oral antihyperglycemic drugs during pregnancy rarely require insulin during labor and delivery.",
"   </p>",
"   <p>",
"    Women with GDM who used insulin or oral antihyperglycemic drugs to maintain euglycemia may need an insulin infusion during labor and delivery to maintain euglycemia. We generally check blood glucose measurements every two hours during labor in these women and we begin an insulin infusion if the values rise above 120",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.7",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Since mild hyperglycemia is generally less morbid and easier to treat than hypoglycemia, it is usually better to withhold long-acting insulin in favor of using an insulin infusion, as needed, in women in labor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/29/2519?source=see_link\">",
"     \"Intrapartum and postpartum management of insulin and blood glucose\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women undergoing scheduled cesarean delivery, insulin or antihyperglycemic drugs are withheld the morning of surgery and the woman is not allowed any oral intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     POSTPARTUM MANAGEMENT AND FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with GDM should be able to resume a regular diet postpartum. Postpartum, the hyperglycemic effects from placental hormones dissipate rapidly. Thus, most women revert back to their prepregnancy glycemic control almost immediately. However, since some women with GDM might have undiagnosed type 2 diabetes mellitus, we check blood glucose concentrations (fasting and after meals) for 24 hours after a vaginal delivery and 48 hours after a cesarean delivery. Women with GDM who have fasting venous glucose levels below 126",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    after delivery can be counseled to continue to follow their diet, exercise, and achieve a healthy weight to prevent future diabetes. If the blood glucose concentrations are elevated, continuation of monitoring and therapy are warranted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/29/2519?source=see_link&amp;anchor=H15#H15\">",
"     \"Intrapartum and postpartum management of insulin and blood glucose\", section on 'Postpartum management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postpartum depression is more common among women with diabetes (pregestational or gestational) than in nondiabetic women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/11/20666?source=see_link\">",
"     \"Postpartum blues and depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any type of contraception is acceptable, as long as the usual medical contraindications to use are absent (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"UTD.htm?12/13/12506\">",
"     table 1",
"    </a>",
"    ). Options in breastfeeding women using anti-hyperglycemic agents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=see_link&amp;anchor=H28#H28\">",
"     \"Principles of medication use during lactation\", section on 'Anti-hyperglycemic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study of Hispanic women with recent GDM who were breastfeeding, the use of progestin-only pills was associated with an increased risk of developing type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/70\">",
"     70",
"    </a>",
"    ]; however, the applicability of these findings to non-Hispanic women is unclear. In another study, depo-medroxyprogesterone acetate (DMPA) use was associated with an increased risk of developing diabetes that the authors attributed to use in women with increased baseline diabetes risk, weight gain during use, and use with high baseline triglycerides",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    during breast-feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4313/abstract/71\">",
"     71",
"    </a>",
"    ]. It is unlikely that the low systemic progesterone level related to use of a levonorgestrel-releasing intrauterine contraceptive would have a similar effect. If a patient is concerned about these hormonal issues, a copper-releasing intrauterine contraceptive is a good alternative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all women (&ge;90 percent) with GDM are normoglycemic after delivery. However, they are at risk for recurrent GDM, and development of impaired glucose tolerance or overt diabetes later in life. Therefore, at least six weeks after delivery, all women with previous GDM should undergo an oral glucose tolerance test using a two-hour 75 gram oral glucose tolerance test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37866?source=see_link&amp;anchor=H25#H25\">",
"     \"Medical management and follow-up of gestational diabetes mellitus\", section on 'Future risks'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/46/12002?source=see_link\">",
"       \"Patient information: Gestational diabetes (diabetes that starts during pregnancy) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/13/32979?source=see_link\">",
"       \"Patient information: Gestational diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with A2 gestational diabetes mellitus (GDM) requiring pharmacologic therapy, we suggest some form of antenatal fetal testing (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The optimal testing regimen has not been established from rigorous studies. We order twice weekly antenatal testing, using a nonstress test with an amniotic fluid index, starting at 32 weeks of gestation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Antenatal fetal testing'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We also suggest induction of labor at 39 weeks of gestation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Potential benefits include lower rates of macrosomia and large for gestational age infants, lower rates of shoulder dystocia, and lower rates of cesarean delivery. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Timing of delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with A1 GDM well-controlled with nutritional medical therapy alone, we suggest no antenatal fetal testing (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Antenatal fetal testing'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We offer the patient induction at 40",
"      <span class=\"nowrap\">",
"       0/7",
"      </span>",
"      weeks of gestation. We recommend induction at 41 weeks of gestation (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Timing of delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest a single third trimester ultrasound to screen for macrosomia (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Assessment of fetal growth'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Scheduled cesarean delivery to avoid birth trauma is typically offered to women with GDM and estimated fetal weight &ge;4500 grams. Such women should be counseled about the poor predictive ability of ultrasound estimates of fetal weight and the risks and benefits of cesarean delivery in the current and future pregnancies. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Scheduled cesarean delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All women with GDM should be screened for impaired glucose tolerance after they are six weeks postpartum. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/1\">",
"      HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008; 358:1991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/2\">",
"      Crowther CA, Hiller JE, Moss JR, et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005; 352:2477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/3\">",
"      Kwik M, Seeho SK, Smith C, et al. Outcomes of pregnancies affected by impaired glucose tolerance. Diabetes Res Clin Pract 2007; 77:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/4\">",
"      Garner P, Okun N, Keely E, et al. A randomized controlled trial of strict glycemic control and tertiary level obstetric care versus routine obstetric care in the management of gestational diabetes: a pilot study. Am J Obstet Gynecol 1997; 177:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/5\">",
"      Hillier TA, Pedula KL, Vesco KK, et al. Excess gestational weight gain: modifying fetal macrosomia risk associated with maternal glucose. Obstet Gynecol 2008; 112:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/6\">",
"      Dooley SL, Metzger BE, Cho NH. Gestational diabetes mellitus. Influence of race on disease prevalence and perinatal outcome in a U.S. population. Diabetes 1991; 40 Suppl 2:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/7\">",
"      Lipscomb KR, Gregory K, Shaw K. The outcome of macrosomic infants weighing at least 4500 grams: Los Angeles County + University of Southern California experience. Obstet Gynecol 1995; 85:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/8\">",
"      Lazer S, Biale Y, Mazor M, et al. Complications associated with the macrosomic fetus. J Reprod Med 1986; 31:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/9\">",
"      Rouse DJ, Owen J. Prophylactic cesarean delivery for fetal macrosomia diagnosed by means of ultrasonography--A Faustian bargain? Am J Obstet Gynecol 1999; 181:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/10\">",
"      B&eacute;rard J, Dufour P, Vinatier D, et al. Fetal macrosomia: risk factors and outcome. A study of the outcome concerning 100 cases &gt;4500 g. Eur J Obstet Gynecol Reprod Biol 1998; 77:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/11\">",
"      Stotland NE, Caughey AB, Breed EM, Escobar GJ. Risk factors and obstetric complications associated with macrosomia. Int J Gynaecol Obstet 2004; 87:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/12\">",
"      Cohen BF, Penning S, Ansley D, et al. The incidence and severity of shoulder dystocia correlates with a sonographic measurement of asymmetry in patients with diabetes. Am J Perinatol 1999; 16:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/13\">",
"      Nesbitt TS, Gilbert WM, Herrchen B. Shoulder dystocia and associated risk factors with macrosomic infants born in California. Am J Obstet Gynecol 1998; 179:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/14\">",
"      Casey BM, Lucas MJ, Mcintire DD, Leveno KJ. Pregnancy outcomes in women with gestational diabetes compared with the general obstetric population. Obstet Gynecol 1997; 90:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/15\">",
"      Yogev Y, Xenakis EM, Langer O. The association between preeclampsia and the severity of gestational diabetes: the impact of glycemic control. Am J Obstet Gynecol 2004; 191:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/16\">",
"      Innes KE, Wimsatt JH, McDuffie R. Relative glucose tolerance and subsequent development of hypertension in pregnancy. Obstet Gynecol 2001; 97:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/17\">",
"      Joffe GM, Esterlitz JR, Levine RJ, et al. The relationship between abnormal glucose tolerance and hypertensive disorders of pregnancy in healthy nulliparous women. Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol 1998; 179:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/18\">",
"      Carpenter MW. Gestational diabetes, pregnancy hypertension, and late vascular disease. Diabetes Care 2007; 30 Suppl 2:S246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/19\">",
"      Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: preeclampsia. Am J Obstet Gynecol 2010; 202:255.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/20\">",
"      Parretti E, Lapolla A, Dalfr&agrave; M, et al. Preeclampsia in lean normotensive normotolerant pregnant women can be predicted by simple insulin sensitivity indexes. Hypertension 2006; 47:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/21\">",
"      Sierra-Laguado J, Garc&iacute;a RG, Celed&oacute;n J, et al. Determination of insulin resistance using the homeostatic model assessment (HOMA) and its relation with the risk of developing pregnancy-induced hypertension. Am J Hypertens 2007; 20:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/22\">",
"      Hauth JC, Clifton RG, Roberts JM, et al. Maternal insulin resistance and preeclampsia. Am J Obstet Gynecol 2011; 204:327.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/23\">",
"      Shoham I, Wiznitzer A, Silberstein T, et al. Gestational diabetes complicated by hydramnios was not associated with increased risk of perinatal morbidity and mortality. Eur J Obstet Gynecol Reprod Biol 2001; 100:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/24\">",
"      Biggio JR Jr, Wenstrom KD, Dubard MB, Cliver SP. Hydramnios prediction of adverse perinatal outcome. Obstet Gynecol 1999; 94:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/25\">",
"      Girz BA, Divon MY, Merkatz IR. Sudden fetal death in women with well-controlled, intensively monitored gestational diabetes. J Perinatol 1992; 12:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/26\">",
"      Aberg A, Rydhstr&ouml;m H, K&auml;ll&eacute;n B, K&auml;ll&eacute;n K. Impaired glucose tolerance during pregnancy is associated with increased fetal mortality in preceding sibs. Acta Obstet Gynecol Scand 1997; 76:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/27\">",
"      Dudley DJ. Diabetic-associated stillbirth: incidence, pathophysiology, and prevention. Obstet Gynecol Clin North Am 2007; 34:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/28\">",
"      Langer O, Rodriguez DA, Xenakis EM, et al. Intensified versus conventional management of gestational diabetes. Am J Obstet Gynecol 1994; 170:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/29\">",
"      Blank A, Grave GD, Metzger BE. Effects of gestational diabetes on perinatal morbidity reassessed. Report of the International Workshop on Adverse Perinatal Outcomes of Gestational Diabetes Mellitus, December 3-4, 1992. Diabetes Care 1995; 18:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/30\">",
"      Hod M, Merlob P, Friedman S, et al. Gestational diabetes mellitus. A survey of perinatal complications in the 1980s. Diabetes 1991; 40 Suppl 2:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/31\">",
"      Boney CM, Verma A, Tucker R, Vohr BR. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics 2005; 115:e290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/32\">",
"      Malcolm JC, Lawson ML, Gaboury I, et al. Glucose tolerance of offspring of mother with gestational diabetes mellitus in a low-risk population. Diabet Med 2006; 23:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/33\">",
"      Gillman MW, Rifas-Shiman S, Berkey CS, et al. Maternal gestational diabetes, birth weight, and adolescent obesity. Pediatrics 2003; 111:e221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/34\">",
"      Silverman BL, Metzger BE, Cho NH, Loeb CA. Impaired glucose tolerance in adolescent offspring of diabetic mothers. Relationship to fetal hyperinsulinism. Diabetes Care 1995; 18:611.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Gestational Diabetes. ACOG practice bulletin #30, American College of Obstetricians and Gynecologists, Washington, DC 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/36\">",
"      Kjos SL, Leung A, Henry OA, et al. Antepartum surveillance in diabetic pregnancies: predictors of fetal distress in labor. Am J Obstet Gynecol 1995; 173:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/37\">",
"      Landon MB, Gabbe SG. Antepartum fetal surveillance in gestational diabetes mellitus. Diabetes 1985; 34 Suppl 2:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/38\">",
"      Gabbe SG, Mestman JG, Freeman RK, et al. Management and outcome of class A diabetes mellitus. Am J Obstet Gynecol 1977; 127:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/39\">",
"      Gonen O, Rosen DJ, Dolfin Z, et al. Induction of labor versus expectant management in macrosomia: a randomized study. Obstet Gynecol 1997; 89:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/40\">",
"      Rouse DJ, Owen J, Goldenberg RL, Cliver SP. The effectiveness and costs of elective cesarean delivery for fetal macrosomia diagnosed by ultrasound. JAMA 1996; 276:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/41\">",
"      Kjos SL, Schaefer-Graf UM. Modified therapy for gestational diabetes using high-risk and low-risk fetal abdominal circumference growth to select strict versus relaxed maternal glycemic targets. Diabetes Care 2007; 30 Suppl 2:S200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/42\">",
"      Engstrom JL, Work BA Jr. Prenatal prediction of small- and large-for-gestational age neonates. J Obstet Gynecol Neonatal Nurs 1992; 21:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/43\">",
"      Humphries J, Reynolds D, Bell-Scarbrough L, et al. Sonographic estimate of birth weight: relative accuracy of sonographers versus maternal-fetal medicine specialists. J Matern Fetal Neonatal Med 2002; 11:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/44\">",
"      Johnstone FD, Prescott RJ, Steel JM, et al. Clinical and ultrasound prediction of macrosomia in diabetic pregnancy. Br J Obstet Gynaecol 1996; 103:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/45\">",
"      McLaren RA, Puckett JL, Chauhan SP. Estimators of birth weight in pregnant women requiring insulin: a comparison of seven sonographic models. Obstet Gynecol 1995; 85:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/46\">",
"      Smith GC, Smith MF, McNay MB, Fleming JE. The relation between fetal abdominal circumference and birthweight: findings in 3512 pregnancies. Br J Obstet Gynaecol 1997; 104:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/47\">",
"      Hackmon R, Bornstein E, Ferber A, et al. Combined analysis with amniotic fluid index and estimated fetal weight for prediction of severe macrosomia at birth. Am J Obstet Gynecol 2007; 196:333.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/48\">",
"      Scioscia M, Scioscia F, Vimercati A, et al. Estimation of fetal weight by measurement of fetal thigh soft-tissue thickness in the late third trimester. Ultrasound Obstet Gynecol 2008; 31:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/49\">",
"      Cromi A, Ghezzi F, Di Naro E, et al. Large cross-sectional area of the umbilical cord as a predictor of fetal macrosomia. Ultrasound Obstet Gynecol 2007; 30:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/50\">",
"      Higgins MF, Russell NM, Mulcahy CH, et al. Fetal anterior abdominal wall thickness in diabetic pregnancy. Eur J Obstet Gynecol Reprod Biol 2008; 140:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/51\">",
"      Ben-Haroush A, Chen R, Hadar E, et al. Accuracy of a single fetal weight estimation at 29-34 weeks in diabetic pregnancies: can it predict large-for-gestational-age infants at term? Am J Obstet Gynecol 2007; 197:497.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/52\">",
"      Little SE, Edlow AG, Thomas AM, Smith NA. Estimated fetal weight by ultrasound: a modifiable risk factor for cesarean delivery? Am J Obstet Gynecol 2012; 207:309.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/53\">",
"      Kjos SL, Henry OA, Montoro M, et al. Insulin-requiring diabetes in pregnancy: a randomized trial of active induction of labor and expectant management. Am J Obstet Gynecol 1993; 169:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/54\">",
"      Lurie S, Insler V, Hagay ZJ. Induction of labor at 38 to 39 weeks of gestation reduces the incidence of shoulder dystocia in gestational diabetic patients class A2. Am J Perinatol 1996; 13:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/55\">",
"      Conway DL, Langer O. Elective delivery of infants with macrosomia in diabetic women: reduced shoulder dystocia versus increased cesarean deliveries. Am J Obstet Gynecol 1998; 178:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/56\">",
"      Lurie S, Matzkel A, Weissman A, et al. Outcome of pregnancy in class A1 and A2 gestational diabetic patients delivered beyond 40 weeks' gestation. Am J Perinatol 1992; 9:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/57\">",
"      Peled Y, Perri T, Chen R, et al. Gestational diabetes mellitus--implications of different treatment protocols. J Pediatr Endocrinol Metab 2004; 17:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/58\">",
"      Witkop CT, Neale D, Wilson LM, et al. Active compared with expectant delivery management in women with gestational diabetes: a systematic review. Obstet Gynecol 2009; 113:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/59\">",
"      Nicholson JM, Kellar LC, Cronholm PF, Macones GA. Active management of risk in pregnancy at term in an urban population: an association between a higher induction of labor rate and a lower cesarean delivery rate. Am J Obstet Gynecol 2004; 191:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/60\">",
"      Nicholson JM, Parry S, Caughey AB, et al. The impact of the active management of risk in pregnancy at term on birth outcomes: a randomized clinical trial. Am J Obstet Gynecol 2008; 198:511.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/61\">",
"      Rosenstein MG, Cheng YW, Snowden JM, et al. The risk of stillbirth and infant death stratified by gestational age in women with gestational diabetes. Am J Obstet Gynecol 2012; 206:309.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/62\">",
"      American College of Obstetricians and Gynecologists. Committee Opinion No. 560. Medically indicated late-preterm and early-term deliveries. Obstet Gynecol 2013; 121:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/63\">",
"      Wiznitzer A, Furman B, Zuili I, et al. Cord leptin level and fetal macrosomia. Obstet Gynecol 2000; 96:707.",
"     </a>",
"    </li>",
"    <li>",
"     ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Fetal Macrosomia. Number 22, November, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/65\">",
"      Silver RM, Landon MB, Rouse DJ, et al. Maternal morbidity associated with multiple repeat cesarean deliveries. Obstet Gynecol 2006; 107:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/66\">",
"      Landon MB, Hauth JC, Leveno KJ, et al. Maternal and perinatal outcomes associated with a trial of labor after prior cesarean delivery. N Engl J Med 2004; 351:2581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/67\">",
"      Caughey AB, Sandberg PL, Zlatnik MG, et al. Forceps compared with vacuum: rates of neonatal and maternal morbidity. Obstet Gynecol 2005; 106:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/68\">",
"      Demissie K, Rhoads GG, Smulian JC, et al. Operative vaginal delivery and neonatal and infant adverse outcomes: population based retrospective analysis. BMJ 2004; 329:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/69\">",
"      Kozhimannil KB, Pereira MA, Harlow BL. Association between diabetes and perinatal depression among low-income mothers. JAMA 2009; 301:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/70\">",
"      Kjos SL, Peters RK, Xiang A, et al. Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. JAMA 1998; 280:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4313/abstract/71\">",
"      Xiang AH, Kawakubo M, Kjos SL, Buchanan TA. Long-acting injectable progestin contraception and risk of type 2 diabetes in Latino women with prior gestational diabetes mellitus. Diabetes Care 2006; 29:613.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4800 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-E002DE631A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_13_4313=[""].join("\n");
var outline_f4_13_4313=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FOCUS OF PRENATAL CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MANAGEMENT OF PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Glucose monitoring and control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Antenatal fetal testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Assessment of fetal growth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Timing of delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Scheduled cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      POSTPARTUM MANAGEMENT AND FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Contraception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4800\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4800|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/13/12506\" title=\"table 1\">",
"      CDC Medical Eligibility Criteria for Contraceptive Use",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42919?source=related_link\">",
"      Assessment of fetal lung maturity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21449?source=related_link\">",
"      Cesarean delivery: Postoperative issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31337?source=related_link\">",
"      Fetal macrosomia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44809?source=related_link\">",
"      Infant of a diabetic mother",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/29/2519?source=related_link\">",
"      Intrapartum and postpartum management of insulin and blood glucose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41752?source=related_link\">",
"      Intrapartum management and outcome of shoulder dystocia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37866?source=related_link\">",
"      Medical management and follow-up of gestational diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20794?source=related_link\">",
"      Medical management of type 1 and type 2 diabetes mellitus in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35818?source=related_link\">",
"      Obstetrical management of pregnancy complicated by pregestational diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30121?source=related_link\">",
"      Overview of fetal assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/46/12002?source=related_link\">",
"      Patient information: Gestational diabetes (diabetes that starts during pregnancy) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/13/32979?source=related_link\">",
"      Patient information: Gestational diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/11/20666?source=related_link\">",
"      Postpartum blues and depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16535?source=related_link\">",
"      Postterm pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=related_link\">",
"      Preeclampsia: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=related_link\">",
"      Pregnancy risks in women with type 1 and type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42487?source=related_link\">",
"      Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41609?source=related_link\">",
"      Prevention of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=related_link\">",
"      Principles of labor induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=related_link\">",
"      Principles of medication use during lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37862?source=related_link\">",
"      Repeat cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9210?source=related_link\">",
"      Screening and diagnosis of diabetes mellitus during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/1/16408?source=related_link\">",
"      Timing and route of delivery in pregnancies at risk of shoulder dystocia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_13_4314="Overview of testosterone deficiency in elderly men";
var content_f4_13_4314=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of testosterone deficiency in elderly men",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/13/4314/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/13/4314/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/13/4314/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/13/4314/contributors\">",
"     Alvin M Matsumoto, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/13/4314/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/13/4314/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/13/4314/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/13/4314/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As men age, their serum concentrations of testosterone and, to a greater extent, free testosterone, decrease. This decline is sometimes referred to as \"andropause\" or \"late-onset hypogonadism.\" However, unlike menopause, where complete estrogen deficiency with known clinical consequences occurs, the decline in testosterone in aging men is modest and the possible clinical consequences have not been well-established.",
"   </p>",
"   <p>",
"    Changes in body function occur in aging men that are similar to the manifestations of hypogonadism due to known disease, raising the possibility that the decline in testosterone production with aging may be a cause of these changes. The question of whether or not testosterone should be administered to elderly men is difficult to answer because it is not known whether testosterone treatment reverses the age-related decline in any function, nor is it known if testosterone treatment exacerbates any of the testosterone-dependent diseases, such as those of the prostate, to which elderly men are prone. The decline in testicular function with aging is reviewed here. Other endocrine changes seen with aging are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/22/12650?source=see_link\">",
"     \"Endocrine changes with aging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHANGES WITH AGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both cross-sectional and longitudinal studies demonstrate a decline in serum testosterone concentration, an increase in sex hormone binding concentration (SHBG), and a decrease in free testosterone with age. It is important to note, however, that most commercially available assays for total and free testosterone (and calculated free testosterone formulae) have both theoretical and technical limitations that hinder a clinician&rsquo;s ability to reliably diagnose hypogonadism in an individual elderly man [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=see_link&amp;anchor=H29710780#H29710780\">",
"     \"Clinical features and diagnosis of male hypogonadism\", section on 'Which form of testosterone should be measured?'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Serum total testosterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several cross-sectional studies show a decline of serum total testosterone concentration with increasing age [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/4-10\">",
"     4-10",
"    </a>",
"    ]. The decline, however, is relatively small. In one study, testosterone declined about 100",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (3.5",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    from age 20 to age 80 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/11\">",
"     11",
"    </a>",
"    ]. Young men exhibit a diurnal variation, with highest values at about 8 AM and lowest about 8 PM, but elderly men have little variation (",
"    <a class=\"graphic graphic_figure graphicRef79127 \" href=\"UTD.htm?40/47/41725\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result of this fall, a greater percentage of elderly men have testosterone values sufficiently low to be considered hypogonadal in young men.",
"   </p>",
"   <p>",
"    In the largest cross-sectional study to date, the European Male Aging Study (EMAS), of 3220 men ages 40 to 79 years, the serum total testosterone concentration fell 0.4 percent a year and the free testosterone concentration fell 1.3 percent a year [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three longitudinal studies also show a decrease in testosterone with increasing age, and in two of them, the decrease was greater than that in cross-sectional studies. In 890 men participating in the Baltimore Longitudinal Study of Aging, serum testosterone decreased at a fairly constant rate, independent of other clinical variables (",
"    <a class=\"graphic graphic_figure graphicRef58511 \" href=\"UTD.htm?21/26/21934\">",
"     figure 2",
"    </a>",
"    ). The percentage of subjects with total testosterone concentrations in the hypogonadal range (defined in this study as total testosterone &lt;325",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    [11.3",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    was 20, 30, and 50 percent for men in their 60s, 70s, and 80s, respectively (",
"    <a class=\"graphic graphic_figure graphicRef65074 \" href=\"UTD.htm?1/61/2014\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Massachusetts Male Aging Study, longitudinal assessment also showed a decrease in total testosterone with increasing age but a greater decrease in free testosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/14\">",
"     14",
"    </a>",
"    ]. The decrease with age was greater if it was accompanied by obesity, a new illness, or a serious emotional stress.",
"   </p>",
"   <p>",
"    In 77 men participating in the New Mexico Aging Process Study, the fall was also much greater when assessed longitudinally than cross-sectionally [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Serum sex hormone-binding globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum sex hormone-binding globulin (SHBG) concentrations increase gradually as a function of age [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/11\">",
"     11",
"    </a>",
"    ]. The clinical implication, because SHBG binds testosterone with high affinity, is that with increasing age, less of the total testosterone is free (ie, biologically active).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Serum free testosterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum free testosterone concentration decreases with increasing age to a greater degree than the total testosterone. In the Baltimore Longitudinal Study of Aging, the percentage of subjects with low estimates of free testosterone was 40, 70, and 90 percent for men in their 60s, 70s, and 80s, respectively (",
"    <a class=\"graphic graphic_figure graphicRef65074 \" href=\"UTD.htm?1/61/2014\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/13\">",
"     13",
"    </a>",
"    ]. In the Massachusetts Male Aging Study, the percent fall in free testosterone was 2.8 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Decline in spermatogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sperm production does not appear to change dramatically with increasing age. Testicular size, which reflects primarily the volume occupied by the seminiferous tubules, was somewhat smaller (mean volume 20.6 mL) in 114 elderly men than in 42 young men (29.7 mL) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/17\">",
"     17",
"    </a>",
"    ]. Ejaculated sperm density in 20 fathers ages 24 to 37 years old was slightly lower than that in 22 grandfathers ages 60 to 88 years old, but percent motility was slightly greater in the younger group, resulting in a similar total number of motile sperm in the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/18\">",
"     18",
"    </a>",
"    ]. In 1174 men recruited for studies of erectile function, the oldest quartile, who were aged 56 to 80 years, had similar semen characteristics to the youngest quartile, aged 45 to 47.8 years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Change in gonadotropins",
"    </span>",
"    &nbsp;&mdash;&nbsp;As men age, serum gonadotropin concentrations increase, FSH more than LH, but the rise is not so great as one would expect from the fall in testosterone, suggesting that the fall in testosterone with aging is due to both secondary and primary hypogonadism. In the New Mexico Aging Process Study, the mean LH concentration increased over 15 years from a mean of 9.4",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    to 13.7",
"    <span class=\"nowrap\">",
"     mIU/mL,",
"    </span>",
"    and the FSH increased from 14.1",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    to 27.4",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/15\">",
"     15",
"    </a>",
"    ]. In the Massachusetts Male Aging Study, the LH increased by 0.9 percent per year and the FSH by 3.1 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/16\">",
"     16",
"    </a>",
"    ]. In the European Male Aging Study, the fall in testosterone with age was associated with an increase in LH, suggesting a degree of primary hypogonadism [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/12\">",
"     12",
"    </a>",
"    ], but the fall in testosterone with obesity itself was not, suggesting that the effect of obesity was mediated by secondary hypogonadism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CONSEQUENCES OF T DECLINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;No consequences of the decline in serum testosterone with age are known with certainty, but several parallels between the effects of aging and those of hypogonadism suggest that the decline in serum testosterone might be a cause of several effects of aging. The parallels include the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Sexual function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual function, measured by frequency of orgasm or intercourse or by sexual satisfaction, is less in elderly men than in young men [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/20\">",
"     20",
"    </a>",
"    ]. Men with hypogonadism due to known disease also have a decline in sexual function, as illustrated by an improvement after testosterone treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=see_link\">",
"     \"Overview of male sexual dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link\">",
"     \"Testosterone treatment of male hypogonadism\"",
"    </a>",
"    .) In 3369 men ages 40 to 79 who were participating in the European Male Aging Study, the only symptoms that were significantly associated with a serum testosterone concentration less than 320",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (11.1",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    were three sexual symptoms (poor morning erection, low sexual desire, and erectile dysfunction) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Bone mineral density and fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;As men age, their bone mineral density declines and their risk of fractures increases. In a study of healthy men who had never had any fractures, the bone mineral density of the femur and, to a lesser extent, the spine, declined from age 20 to age 90 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/23\">",
"     23",
"    </a>",
"    ]. Men who are hypogonadal due to disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/24\">",
"     24",
"    </a>",
"    ] or whose testosterone has been lowered surgically [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/25\">",
"     25",
"    </a>",
"    ] or medically [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/26,27\">",
"     26,27",
"    </a>",
"    ] also have a decline in bone mineral density. In a prospective cohort study of men over age 65, the risk of nonvertebral fractures was increased in those who had low serum concentrations of bioavailable estradiol or high SHBG but not in those who had only a low bioavailable testosterone. Risk was greatest (HR 3.4 [2.2 to 5.3]) in men with low bioavailable estradiol and testosterone and high SHBG [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Muscle and fat mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;As men age, their muscle mass declines and fat mass increases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/29\">",
"     29",
"    </a>",
"    ]. Hypogonadal men also have less muscle mass and more fat mass than normal men; testosterone treatment in men with hypogonadism tends to reverse these changes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Muscle strength",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men aged 60 to 79 years have less muscle strength than those aged 20 to 39 years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/30\">",
"     30",
"    </a>",
"    ]. There are a few studies comparing muscle strength in hypogonadal men to that in normal men. When six normal young men were made hypogonadal by administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    for 10 weeks, strength of knee extension at 60&ordm; angular velocity by Biodex dynamometer was about 10 percent less than when they were eugonadal [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/31\">",
"     31",
"    </a>",
"    ]. Conversely, when hypogonadal men were treated with 100 mg of testosterone enanthate once a week for 10 weeks, their strength increased in bench press by 22 percent and in squat strength by 45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/32\">",
"     32",
"    </a>",
"    ]. In another study, however, transdermal testosterone treatment of hypogonadal men for three years did not increase strength of knee extension or flexion by Biodex dynamometer at 60&ordm; angular velocity or hand grip strength [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4543601\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia is very common in elderly men. In one population-based study, 14 of 99 men in the lowest quartile of testosterone were anemic compared with only 3 of 100 in the highest quartile (odds ratio 5.4; 95% CI 1.4-21.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/34\">",
"     34",
"    </a>",
"    ]. Anemia is also common in severe hypogonadism and is readily corrected when testosterone is replaced [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/33\">",
"     33",
"    </a>",
"    ]. In placebo-controlled trials in elderly men, testosterone treatment results in an increase in hemoglobin when compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/35\">",
"     35",
"    </a>",
"    ], but correction of anemia has not yet been demonstrated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7730159\">",
"    <span class=\"h2\">",
"     Mood",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Longitudinal Aging Study Amsterdam, 608 men aged &ge;65 years were observed yearly for three years for serum testosterone and Center of Epidemiologic Studies-Depression Scale (CES-D) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/36\">",
"     36",
"    </a>",
"    ]. Serum free testosterone concentrations below a threshold were associated with depressive symptoms, even after correction for possible confounders, and men in the lowest quintile for free testosterone were at greater risk for development of depressive symptoms than those in the upper four quintiles. In hypogonadal men, raising the serum testosterone concentration improved mood [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cognitive function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decrease in serum testosterone concentrations that occurs with aging in men may be associated with a decline in neuropsychological function. In a longitudinal study of 407 men ages 50 to 91 years, men classified as hypogonadal by serum free testosterone index (calculated by dividing serum testosterone by SHBG) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/38\">",
"     38",
"    </a>",
"    ] had significantly lower scores on measures of verbal and visual memory and visuospatial performance and a faster rate of decline in visual memory. However, neither young nor elderly healthy men who were made severely hypogonadal with a GnRH agonist for six weeks had scored differently on tests of cognition than did men who were treated with the agonist but had their serum testosterone concentration maintained within the normal range by concomitant administration of testosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Metabolic cardiovascular parameters",
"    </span>",
"    &nbsp;&mdash;&nbsp;In epidemiologic studies, low serum testosterone concentrations have been associated with the subsequent development of central obesity, higher insulin concentrations, the metabolic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/40,41\">",
"     40,41",
"    </a>",
"    ], diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/41,42\">",
"     41,42",
"    </a>",
"    ], high sensitivity C-reactive protein [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/43\">",
"     43",
"    </a>",
"    ], and increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/44-46\">",
"     44-46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356931\">",
"    <span class=\"h1\">",
"     IS THERE A SYNDROME OF HYPOGONADISM IN ELDERLY MEN?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men of any age who have severe hypogonadism due to pituitary or testicular disease usually have manifestations of the hypogonadism, including low muscle mass, bone density, energy, and sexual interest, as well as anemia and impaired glucose tolerance. A report from the European Male Aging Study described the evaluation of 3369 men aged 40 to 79 to determine if men with a low serum testosterone concentration for no apparent reason other than age develop the typical signs and symptoms of male hypogonadism due to known pituitary or testicular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/47\">",
"     47",
"    </a>",
"    ]. The combination of low serum testosterone (&lt;317",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    [11",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    and three sexual symptoms, which occurred in 2.3 percent of men, was significantly associated with lower hemoglobin, estimated heel bone mineral density mid-upper arm circumference, and physical performance. More severe hypogonadism (serum testosterone concentration &lt;230",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    [8",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    was also associated with insulin resistance. The associations were stronger when the serum testosterone concentration was &lt;230",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (8",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    than when it was in the 230 to 317",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    range (8 to 11 nM). These data support the concept of a low testosterone syndrome in middle aged and elderly men, but only in a small percentage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TESTOSTERONE ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the clinical observations described above suggest that the decline in testosterone with age may have several adverse consequences, the impact of testosterone replacement in older men with low serum testosterone and hypogonadal symptoms remains unclear. Trials have been limited by small sample size, inclusion of asymptomatic men with low-normal testosterone levels, and variable testosterone regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/48\">",
"     48",
"    </a>",
"    ]. A committee of the Institute of Medicine of the National Academy of Sciences Committee reviewed available studies and concluded that no beneficial effects of administering testosterone have been well established [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, other expert groups argue that there may be a role for testosterone therapy in selected patients. The Endocrine Society first published evidence-based clinical guidelines for testosterone therapy in adult men with testosterone deficiency in 2006; updated guidelines were published in 2010. We agree with their approach in elderly men, which is outlined below. (See",
"    <a class=\"local\" href=\"#H313824889\">",
"     'Suggested approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the absence of known pituitary or testicular disease, we suggest testosterone therapy only for men with low serum testosterone concentrations on more than one occasion and symptoms of testosterone deficiency. Clinicians must discuss the uncertainty about the risks and benefits of testosterone therapy before recommending this approach.",
"     </li>",
"     <li>",
"      The target serum testosterone concentration in these men should be lower than that for younger men, for example, 300 to 400",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      (10.4 to 13.9",
"      <span class=\"nowrap\">",
"       nmol/L),",
"      </span>",
"      rather than 500 to 600",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      (17.4 to 20.8",
"      <span class=\"nowrap\">",
"       nmol/L),",
"      </span>",
"      to minimize the potential risk of testosterone-dependent diseases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H252464115\">",
"    <span class=\"h2\">",
"     Clinical trial data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data come from five randomized, placebo-controlled trials including over 500 elderly men [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/35,50-55\">",
"     35,50-55",
"    </a>",
"    ]. However, only three of the trials raised serum testosterone into the normal range for young men. In those three trials, a number of outcomes were evaluated as described in this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Bone density",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one study, testosterone treatment for three years did not increase bone mineral density (BMD) in the spine or hip compared with placebo, but a secondary analysis showed that the lower the pretreatment serum testosterone concentration, the greater the testosterone treatment effect on spine BMD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/35\">",
"     35",
"    </a>",
"    ]. In the second report, testosterone treatment for one year did not increase spine BMD compared with placebo but prevented a decrease in hip BMD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/51\">",
"     51",
"    </a>",
"    ]. In the third study, in which the serum testosterone concentrations were raised to higher than mid-normal for young men [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/52\">",
"     52",
"    </a>",
"    ], testosterone treatment, without and with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    , significantly increased spine BMD by 10.2 and 9.3 percent at the spine and 2.7 and 2.2 percent at the hip, respectively.",
"   </p>",
"   <p>",
"    A meta-analysis of the eight trials of a total of 365 patients concluded that the trials that employed intramuscular testosterone esters showed a modest improvement in spine (but not femoral neck) BMD, but transdermal testosterone did not [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/56\">",
"     56",
"    </a>",
"    ]. The authors also concluded that in the absence of bone fracture data, the trials offered weak and indirect inferences about the efficacy of testosterone on osteoporosis in men.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Body composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testosterone significantly affected body composition, increasing fat free (mostly lean) mass (1.9 kg, 1.1 kg, and 3.7 kg) and decreasing fat mass (-3.0 kg, &ndash;1.1 kg, and -4.5 kg) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/50,51,53\">",
"     50,51,53",
"    </a>",
"    ]. In a systematic review of seven trials, performed as part of the 2008 Endocrine Society Guidelines, testosterone therapy was associated with a significantly greater increase in lean body mass (2.7 kg; 95% CI, 1.6-3.7) and a greater reduction in fat mass (-2.0 kg; 95% CI 3.1-0.8) than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/57\">",
"     57",
"    </a>",
"    ]. The body weight change did not differ significantly between groups (-0.6 kg; 95% CI -2.0-0.8).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Muscle strength",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increase in lean mass was not accompanied by increases in muscle strength, either of knee extension and flexion or hand grip strength in one trial [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/50\">",
"     50",
"    </a>",
"    ], or of leg press strength in another [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/51\">",
"     51",
"    </a>",
"    ]. In the third trial, hand grip strength increased, but knee and ankle strength did not [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Physical function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testosterone treatment was also not accompanied by improvement in various parameters of physical function in the first two trials [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/50,51\">",
"     50,51",
"    </a>",
"    ], but in the third was associated with an increase in a composite physical performance test [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testosterone treatment was not accompanied by improvement in quality of life in two trials [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/35,51\">",
"     35,51",
"    </a>",
"    ] or sexual function in one [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/35\">",
"     35",
"    </a>",
"    ], as judged by questionnaires. In a meta-analysis of 17 trials, those that enrolled subjects with a low testosterone showed a large effect on libido, but little or no effect on erectile function and sexual satisfaction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2560094\">",
"    <span class=\"h3\">",
"     Mood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two small but randomized, double-blind, placebo-controlled studies showed a beneficial effect of testosterone on mood. In a study of 33 men of mean age 59 with serum testosterone concentrations &lt;280",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (&lt;9.7",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    and subthreshold depression, treatment with testosterone gel for 12 weeks (n = 17) resulted in a greater reduction in Hamilton Rating Scale for Depression score and higher remission rate of subclinical depression (52.9 percent versus 18.8 percent) than did placebo gel (n = 16) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/59\">",
"     59",
"    </a>",
"    ]. In another study of 23 men of mean age 50 and testosterone 339",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (11.8",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    treatment with testosterone cypionate 200 mg every 10 days for six weeks (n = 13) resulted in a significantly greater decrease in the mean Hamilton Depression Rating Scale score and greater rate of remission than did placebo treatment (n = 10) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the basis of most of the studies described above and others, the Institute of Medicine's committee on testosterone concluded that there is insufficient evidence to conclude that testosterone treatment of elderly men has any well-established benefit. The committee recommended that a coordinated set of randomized, placebo-controlled clinical trials should be performed to determine if testosterone does improve muscle strength, physical function and frailty, vitality, sexual function, cognition, and quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Until the results of such studies are available, we recommend more conservative criteria for testosterone treatment of elderly men who have low testosterone for no apparent reason other than age, than for men who have obvious pituitary, hypothalamic, or gonadal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Potential harmful effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even if testosterone administration is proven to prevent or reverse the age-related declines in some functions, there is reason to wonder if it will also exacerbate testosterone-dependent diseases to which elderly men are particularly prone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Prostate cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostate cancer is partly testosterone-dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/61\">",
"     61",
"    </a>",
"    ]. This dependency is illustrated by the current practice of treating men who have metastatic and locally advanced prostate cancer by lowering their serum testosterone concentrations with gonadotropin-releasing hormone (GnRH) analogs, both agonists and antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/62\">",
"     62",
"    </a>",
"    ], sometimes combined with blocking its action with androgen receptor antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the few clinical trials of testosterone in elderly men, few cases of prostate cancer occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/35,51,52\">",
"     35,51,52",
"    </a>",
"    ], but these trials, involving at most 108 men, had too little statistical power to state that testosterone treatment does not increase the risk of prostate cancer. It has been estimated that a trial would require 6000 men randomized to receive testosterone or placebo for five years each to determine if testosterone increases the incidence of prostate cancer by 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the effect of long-term testosterone therapy on prostate cancer risk in older men is unknown, short-term therapy does not appear to have significant adverse effects on prostate tissue. This was illustrated in a clinical trial of 44 men (average age 68 to 70 years) with \"late-onset\" hypogonadism (based upon a validated androgen deficiency questionnaire and a serum total testosterone concentration &lt;300",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    [10.4",
"    <span class=\"nowrap\">",
"     nmol/L]),",
"    </span>",
"    who were randomly assigned to receive testosterone enanthate (150 intramuscularly every two weeks) or a placebo injection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/64\">",
"     64",
"    </a>",
"    ]. After six months of therapy, the following effects of testosterone therapy were seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mean serum total testosterone concentrations increased with testosterone therapy from 282 to 640",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      (9.8 to 22.2",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      at zero and six months, respectively.",
"     </li>",
"     <li>",
"      Serum PSA concentrations increased, but remained in the normal range (1.55 and 2.29",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      at zero and six months, respectively).",
"     </li>",
"     <li>",
"      While prostate volume and urinary symptoms were unchanged, there was a small but nonsignificant decrease in urinary maximal flow rate.",
"     </li>",
"     <li>",
"      On prostate biopsy, median baseline prostate tissue concentrations of testosterone (0.91",
"      <span class=\"nowrap\">",
"       ng/g)",
"      </span>",
"      and dihydrotestosterone (6.8",
"      <span class=\"nowrap\">",
"       ng/g)",
"      </span>",
"      did not change significantly, despite the increases in serum testosterone concentrations.",
"     </li>",
"     <li>",
"      No significant changes in prostate histology, tissue biomarkers, and gene expression were seen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although short-term testosterone therapy did not result in significant adverse effects on prostate tissue in this trial, a much larger trial of longer duration would be needed to rule out a significant effect on prostate cancer risk.",
"   </p>",
"   <p>",
"    In a 2005 meta-analysis of 19 randomized trials in older men, the combined rate of all prostate events was significantly higher in testosterone-treated men than placebo-treated men (odds ratio 1.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/65\">",
"     65",
"    </a>",
"    ]. Rates of PSA &gt;4",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and prostate cancer were higher in the testosterone group, but the rate of prostate biopsy was also higher in the testosterone group, raising the possibility that the higher rate of prostate cancer was due to ascertainment bias.",
"   </p>",
"   <p>",
"    In a 2010 meta-analysis of 51 randomized trials of testosterone therapy in men designed to look at the primary endpoints of mortality, cardiovascular events and risk factors, prostate outcomes and erythrocytosis, testosterone treatment was not associated with increased incidence of prostate cancer, need for prostate biopsy, or other prostate outcomes when compared with the",
"    <span class=\"nowrap\">",
"     placebo/nonintervention",
"    </span>",
"    group [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/66\">",
"     66",
"    </a>",
"    ]. Results were the same when analyzed by subject age (&lt; or &gt; age 65 years). However, as the authors emphasize, the number of subjects studied and the quality of the observations were not adequate to say that testosterone does not result in worse prostate outcomes.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Benign prostatic hyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The testosterone-dependency of benign prostatic hyperplasia has been known for over 100 years and is the basis for one current medical treatment: use of the 5-alpha-reductase inhibitors",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    to block the conversion of testosterone to dihydrotestosterone, its active metabolite within the prostate [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/67\">",
"     67",
"    </a>",
"    ]. Clinical trials conducted so far have also been too small to draw any conclusions about the possible exacerbation of benign prostatic hyperplasia. In the meta-analysis noted above, testosterone therapy had no adverse effect on lower urinary tract symptoms or other prostate outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/66\">",
"     66",
"    </a>",
"    ], but the number of men observed and the quality of observations were not sufficient to say that testosterone does not worsen lower urinary tract symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=see_link\">",
"     \"Medical treatment of benign prostatic hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Sleep apnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from a small number of men with hypogonadism suggest that even physiologic replacement of testosterone increases sleep apnea [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/68-70\">",
"     68-70",
"    </a>",
"    ], a condition to which elderly men are already prone. In contrast, in the meta-analysis described above [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/65\">",
"     65",
"    </a>",
"    ], the frequency of sleep apnea did not differ between testosterone and placebo-treated men.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Erythrocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testosterone treatment of elderly men, especially with long-acting testosterone esters in doses that have been commonly employed, causes erythrocytosis. In one retrospective trial of 45 men whose average age was 71.8 years and who had relatively low serum bioavailable testosterone concentrations, treatment with 200 mg of testosterone ester (enanthate or cypionate) caused an increase in hematocrit to &gt;52 percent in 11 of them (24 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the trial described above in which men were randomized to receive testosterone enanthate 200",
"    <span class=\"nowrap\">",
"     mg/two",
"    </span>",
"    weeks alone or with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    , 14 of 46 men developed an elevated hemoglobin [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a meta-analysis of nine trials that evaluated hemoglobin and five that evaluated hematocrit, men treated with testosterone, compared with men treated with placebo had higher levels of each (weighted mean difference 0.80",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    for hemoglobin and 3.18 percent for hematocrit) and were more likely to develop erythrocytosis (RR 3.15%; CI 1.56-6.35).",
"   </p>",
"   <p>",
"    The potential significance of this adverse effect is that in the Framingham study, men who were in the highest quintile (46 to 70 percent) with regard to hematocrit had greater overall mortality and cardiovascular mortality than those in the middle two quintiles [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Serum lipids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testosterone replacement therapy in men with hypogonadism has little effect on serum concentrations of total and low-density lipoprotein (LDL) cholesterol. Both oral and intramuscular administration of testosterone have been shown to decrease high-density lipoprotein (HDL) cholesterol concentrations in young hypogonadal men and in men receiving GnRH antagonists, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. In a meta-analysis of 10 studies of intramuscular testosterone esters and plasma lipids in hypogonadal men, a small, dose-dependent decrease was seen in total cholesterol, LDL, and HDL [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/75\">",
"     75",
"    </a>",
"    ]. In older men, transdermal preparations do not decrease HDL [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H252464159\">",
"    <span class=\"h3\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testosterone treatment of hypogonadal men has generally not been associated with increased cardiovascular risk, as shown in the meta-analysis described above [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/66\">",
"     66",
"    </a>",
"    ]. Lack of association of testosterone treatment with adverse cardiovascular events was also true in a subgroup analysis of men &gt;65 years.",
"   </p>",
"   <p>",
"    However, in a trial of 209 men over age 65 years with limitations in mobility and a serum testosterone between 100 and 350",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (3.4-12.2",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    or a free testosterone less than 50",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (173",
"    <span class=\"nowrap\">",
"     pmol/L)",
"    </span>",
"    randomized to testosterone gel or placebo gel for six months, more adverse cardiovascular events were seen in the testosterone group (23 versus 5, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/77\">",
"     77",
"    </a>",
"    ]. The reason for the difference between the results of this study and previous studies is not known. One possible reason is that men in this study had a high prevalence of cardiovascular risk factors including hypertension, diabetes, dyslipidemia, and obesity. Although this observation is of concern, the small size of the trial, small number of events, and the high-risk population studied limits its generalizability.",
"   </p>",
"   <p>",
"    In contrast, no increase in cardiovascular events was reported in a randomized, placebo-controlled trial of testosterone versus placebo in 274 slightly frail elderly men with slightly low serum testosterone concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H313824889\">",
"    <span class=\"h1\">",
"     SUGGESTED APPROACH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H313824901\">",
"    <span class=\"h2\">",
"     Candidates for testosterone",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If a man has symptoms or conditions that suggest testosterone deficiency, such as decreased libido, energy, or mood, or osteoporosis or anemia, we suggest measuring the serum total testosterone concentration early in the morning (eg, 8 AM). If it is less than 300",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      (10.4",
"      <span class=\"nowrap\">",
"       nmol/L),",
"      </span>",
"      we suggest measuring it twice more, since testosterone concentrations fluctuate.",
"     </li>",
"     <li>",
"      Free testosterone should be measured (by equilibrium dialysis or calculated from total testosterone and SHBG) only in men who are obese.",
"     </li>",
"     <li>",
"      If the total testosterone is less than 200",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      (6.9",
"      <span class=\"nowrap\">",
"       nmol/L),",
"      </span>",
"      we recommend evaluation for known causes of hypogonadism. In the absence of documented pituitary or testicular disease, we recommend considering treatment with testosterone only if the testosterone concentration is consistently less than 200",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      (6.9",
"      <span class=\"nowrap\">",
"       nmol/L),",
"      </span>",
"      and only after discussion with the patient of the potential benefits and risks [",
"      <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/79\">",
"       79",
"      </a>",
"      ]. (This recommendation is the same as by some members of the Endocrine Societies Clinical Guidelines Committee, but more stringent than recommended by others.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10044329\">",
"    <span class=\"h2\">",
"     Testosterone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testosterone preparations, dosing, and monitoring are reviewed separately. If the decision is made to treat an elderly man who has a low testosterone concentration for no apparent reason other than age, the target serum testosterone concentration should be",
"    <strong>",
"     lower",
"    </strong>",
"    than that for younger men, for example, 300 to 400",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (10.4 to 13.9",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    rather than 500 to 600",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (17.4 to 20.8",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    to minimize the potential risk of testosterone-dependent diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/13/4314/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If treatment is undertaken, the clinical outcomes for success should be well defined. If the symptoms or condition that led to measuring testosterone is not corrected in the expected period of time (eg, improvement in energy, libido, or hemoglobin in a few months or bone mineral density in two years), discontinuation of the treatment should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H611229941\">",
"    <span class=\"h3\">",
"     Suggested prostate monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a practical approach, we agree with the Endocrine Society&rsquo;s 2010 Clinical Guidelines.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Before initiating testosterone replacement, a digital rectal examination should be performed and serum PSA should be measured. In men who have a prostate nodule or a serum PSA greater than 4.0",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      with no identifiable risk factors or 3.0",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      at increased risk, such as African-Americans or men with a family history of prostate cancer, urologic evaluation should be performed before testosterone treated is initiated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Three months after initiating testosterone replacement, the digital rectal examination and PSA measurement should be repeated. If a nodule has developed or if the PSA has increased more than 1.4",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      above baseline, confirmed by another measurement, urologic consultation should be sought. Thereafter, digital rectal examination and PSA measurement should be performed once a year, as in any man. An increase in PSA of more than 0.4",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      per year, confirmed by repeat measurement, should also lead to urologic consultation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/45/36562?source=see_link\">",
"       \"Patient information: Androgen replacement in men (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/9/18578?source=see_link\">",
"       \"Patient information: Low testosterone in men (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum total testosterone concentrations fall with increasing age, and free testosterone concentrations fall even more. This fall might have adverse consequences on energy, sexual function, muscle mass and function, erythropoiesis, and bone. Some of the decline in testosterone is related to the development of obesity and other comorbidities such as diabetes mellitus; evaluation and management of these comorbidities is therefore essential. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Serum total testosterone'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=see_link&amp;anchor=H24#H24\">",
"       \"Causes of secondary hypogonadism in males\", section on 'Diabetes mellitus'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Elderly men with unequivocally low serum testosterone concentrations (less than 200",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      [6.9",
"      <span class=\"nowrap\">",
"       nmol/L])",
"      </span>",
"      should undergo the same diagnostic evaluation for hypogonadism as a young man with a low testosterone. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=see_link\">",
"       \"Clinical features and diagnosis of male hypogonadism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It is unclear if increasing the serum testosterone concentrations of elderly men to those of young men will prevent or reverse these changes. While there might be clinical benefits of testosterone administration in selected elderly hypogonadal men, the increase in serum testosterone might increase one or more testosterone-dependent diseases to which elderly men are prone. (See",
"      <a class=\"local\" href=\"#H10044329\">",
"       'Testosterone therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Endocrine Society updated its evidence-based clinical guidelines for testosterone therapy in adult men with androgen deficiency in 2010. We generally agree with their approach in elderly men and suggest the following (see",
"      <a class=\"local\" href=\"#H313824889\">",
"       'Suggested approach'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In the absence of known pituitary or testicular disease, we suggest testosterone therapy only for men with low serum testosterone concentrations on more than one occasion and symptoms of testosterone deficiency (such as decreased energy and libido) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Clinicians should attempt to convey to their patients the uncertainty about the risks and benefits of testosterone therapy before prescribing testosterone treatment. (See",
"      <a class=\"local\" href=\"#H313824901\">",
"       'Candidates for testosterone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The target serum testosterone concentration in these men should be lower than that for younger men, for example, 300 to 400",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      (10.4 to 13.9",
"      <span class=\"nowrap\">",
"       nmol/L),",
"      </span>",
"      rather than 500 to 600",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      (17.4 to 20.8",
"      <span class=\"nowrap\">",
"       nmol/L),",
"      </span>",
"      to minimize the potential risk of testosterone-dependent diseases. (See",
"      <a class=\"local\" href=\"#H10044329\">",
"       'Testosterone therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If treatment is undertaken, the man should be screened before treatment and monitored during treatment for evidence of testosterone-dependent diseases, such as prostate cancer. Testosterone treatment should not be initiated in a man with a prostate nodule by digital rectal examination or a PSA greater than 4.0",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (or greater than 3.0",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      if he has a family history of prostate cancer or is African American) without urologic consultation. After beginning treatment, a man should be monitored by digital rectal examination and by PSA at three months and then yearly. If a prostate nodule is detected at any time or the PSA increases by 1.4",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      at three months or 0.4",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      per year thereafter (confirmed by repeat measurement), urologic consultation should be obtained. (See",
"      <a class=\"local\" href=\"#H611229941\">",
"       'Suggested prostate monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specifics on dosing and regimens for testosterone administration are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link\">",
"       \"Testosterone treatment of male hypogonadism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If treatment is undertaken, the clinical outcomes for success should be well defined. If the symptoms or condition that led to measuring testosterone is not corrected in the expected period of time (eg, improvement in energy, libido, or hemoglobin in a few months or bone mineral density in two years), discontinuation of the treatment should be considered. (See",
"      <a class=\"local\" href=\"#H10044329\">",
"       'Testosterone therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/1\">",
"      Sikaris K, McLachlan RI, Kazlauskas R, et al. Reproductive hormone reference intervals for healthy fertile young men: evaluation of automated platform assays. J Clin Endocrinol Metab 2005; 90:5928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/2\">",
"      Rosner W, Auchus RJ, Azziz R, et al. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 2007; 92:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/3\">",
"      Ly LP, Sartorius G, Hull L, et al. Accuracy of calculated free testosterone formulae in men. Clin Endocrinol (Oxf) 2010; 73:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/4\">",
"      Vermeulen A, Rubens R, Verdonck L. Testosterone secretion and metabolism in male senescence. J Clin Endocrinol Metab 1972; 34:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/5\">",
"      Rubens R, Dhont M, Vermeulen A. Further studies on Leydig cell function in old age. J Clin Endocrinol Metab 1974; 39:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/6\">",
"      Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 1983; 56:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/7\">",
"      Winters SJ, Sherins RJ, Troen P. The gonadotropin-suppressive activity of androgen is increased in elderly men. Metabolism 1984; 33:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/8\">",
"      Deslypere JP, Vermeulen A. Leydig cell function in normal men: effect of age, life-style, residence, diet, and activity. J Clin Endocrinol Metab 1984; 59:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/9\">",
"      Tenover JS, Matsumoto AM, Plymate SR, Bremner WJ. The effects of aging in normal men on bioavailable testosterone and luteinizing hormone secretion: response to clomiphene citrate. J Clin Endocrinol Metab 1987; 65:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/10\">",
"      Korenman SG, Morley JE, Mooradian AD, et al. Secondary hypogonadism in older men: its relation to impotence. J Clin Endocrinol Metab 1990; 71:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/11\">",
"      Purifoy FE, Koopmans LH, Mayes DM. Age differences in serum androgen levels in normal adult males. Hum Biol 1981; 53:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/12\">",
"      Wu FC, Tajar A, Pye SR, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 2008; 93:2737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/13\">",
"      Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/14\">",
"      Travison TG, Araujo AB, Kupelian V, et al. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab 2007; 92:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/15\">",
"      Morley JE, Kaiser FE, Perry HM 3rd, et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997; 46:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/16\">",
"      Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002; 87:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/17\">",
"      Mahmoud AM, Goemaere S, El-Garem Y, et al. Testicular volume in relation to hormonal indices of gonadal function in community-dwelling elderly men. J Clin Endocrinol Metab 2003; 88:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/18\">",
"      Nieschlag E, Lammers U, Freischem CW, et al. Reproductive functions in young fathers and grandfathers. J Clin Endocrinol Metab 1982; 55:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/19\">",
"      Hellstrom WJ, Overstreet JW, Sikka SC, et al. Semen and sperm reference ranges for men 45 years of age and older. J Androl 2006; 27:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/20\">",
"      Davidson JM, Chen JJ, Crapo L, et al. Hormonal changes and sexual function in aging men. J Clin Endocrinol Metab 1983; 57:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/21\">",
"      Kwan M, Greenleaf WJ, Mann J, et al. The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men. J Clin Endocrinol Metab 1983; 57:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/22\">",
"      Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010; 363:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/23\">",
"      Riggs BL, Wahner HW, Seeman E, et al. Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes. J Clin Invest 1982; 70:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/24\">",
"      Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996; 81:4358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/25\">",
"      St��p&aacute;n JJ, Lachman M, Zv��rina J, et al. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 1989; 69:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/26\">",
"      Kiratli BJ, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 2001; 57:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/27\">",
"      Stoch SA, Parker RA, Chen L, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 2001; 86:2787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/28\">",
"      LeBlanc ES, Nielson CM, Marshall LM, et al. The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. J Clin Endocrinol Metab 2009; 94:3337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/29\">",
"      Forbes GB, Reina JC. Adult lean body mass declines with age: some longitudinal observations. Metabolism 1970; 19:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/30\">",
"      Murray MP, Gardner GM, Mollinger LA, Sepic SB. Strength of isometric and isokinetic contractions: knee muscles of men aged 20 to 86. Phys Ther 1980; 60:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/31\">",
"      Mauras N, Hayes V, Welch S, et al. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab 1998; 83:1886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/32\">",
"      Bhasin S, Storer TW, Berman N, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997; 82:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/33\">",
"      Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000; 85:2670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/34\">",
"      Ferrucci L, Maggio M, Bandinelli S, et al. Low testosterone levels and the risk of anemia in older men and women. Arch Intern Med 2006; 166:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/35\">",
"      Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84:1966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/36\">",
"      Joshi D, van Schoor NM, de Ronde W, et al. Low free testosterone levels are associated with prevalence and incidence of depressive symptoms in older men. Clin Endocrinol (Oxf) 2010; 72:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/37\">",
"      Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000; 85:2839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/38\">",
"      Moffat SD, Zonderman AB, Metter EJ, et al. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab 2002; 87:5001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/39\">",
"      Young LA, Neiss MB, Samuels MH, et al. Cognition is not modified by large but temporary changes in sex hormones in men. J Clin Endocrinol Metab 2010; 95:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/40\">",
"      Kupelian V, Page ST, Araujo AB, et al. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006; 91:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/41\">",
"      Laaksonen DE, Niskanen L, Punnonen K, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/42\">",
"      Oh JY, Barrett-Connor E, Wedick NM, et al. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 2002; 25:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/43\">",
"      Kaplan SA, Johnson-Levonas AO, Lin J, et al. Elevated high sensitivity C-reactive protein levels in aging men with low testosterone. Aging Male 2010; 13:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/44\">",
"      Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008; 93:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/45\">",
"      Tivesten A, Vandenput L, Labrie F, et al. Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab 2009; 94:2482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/46\">",
"      Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006; 166:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/47\">",
"      Tajar A, Huhtaniemi IT, O'Neill TW, et al. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab 2012; 97:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/48\">",
"      Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95:2536.",
"     </a>",
"    </li>",
"    <li>",
"     Testosterone and aging: Clinical research directions, Liverman CT, Blazer DG (Eds), National Academies Press, Washington DC 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/50\">",
"      Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999; 84:2647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/51\">",
"      Kenny AM, Prestwood KM, Gruman CA, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2001; 56:M266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/52\">",
"      Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004; 89:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/53\">",
"      Page ST, Amory JK, Bowman FD, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 2005; 90:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/54\">",
"      Nair KS, Rizza RA, O'Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006; 355:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/55\">",
"      Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA 2008; 299:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/56\">",
"      Tracz MJ, Sideras K, Bolo&ntilde;a ER, et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab 2006; 91:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/57\">",
"      Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91:1995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/58\">",
"      Isidori AM, Lenzi A. Testosterone replacement therapy: what we know is not yet enough. Mayo Clin Proc 2007; 82:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/59\">",
"      Shores MM, Kivlahan DR, Sadak TI, et al. A randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression). J Clin Psychiatry 2009; 70:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/60\">",
"      Seidman SN, Orr G, Raviv G, et al. Effects of testosterone replacement in middle-aged men with dysthymia: a randomized, placebo-controlled clinical trial. J Clin Psychopharmacol 2009; 29:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/61\">",
"      Huggins, C, Hodges, CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/62\">",
"      Trachtenberg J, Gittleman M, Steidle C, et al. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002; 167:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/63\">",
"      Iversen P, Christensen MG, Friis E, et al. A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate. Cancer 1990; 66:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/64\">",
"      Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006; 296:2351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/65\">",
"      Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005; 60:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/66\">",
"      Fern&aacute;ndez-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010; 95:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/67\">",
"      Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992; 327:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/68\">",
"      Matsumoto AM, Sandblom RE, Schoene RB, et al. Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives, and sleep. Clin Endocrinol (Oxf) 1985; 22:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/69\">",
"      Schneider BK, Pickett CK, Zwillich CW, et al. Influence of testosterone on breathing during sleep. J Appl Physiol 1986; 61:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/70\">",
"      Liu PY, Yee B, Wishart SM, et al. The short-term effects of high-dose testosterone on sleep, breathing, and function in older men. J Clin Endocrinol Metab 2003; 88:3605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/71\">",
"      Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 1997; 82:3793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/72\">",
"      Gagnon DR, Zhang TJ, Brand FN, Kannel WB. Hematocrit and the risk of cardiovascular disease--the Framingham study: a 34-year follow-up. Am Heart J 1994; 127:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/73\">",
"      Asscheman H, Gooren LJ, Megens JA, et al. Serum testosterone level is the major determinant of the male-female differences in serum levels of high-density lipoprotein (HDL) cholesterol and HDL2 cholesterol. Metabolism 1994; 43:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/74\">",
"      Bagatell CJ, Knopp RH, Vale WW, et al. Physiologic testosterone levels in normal men suppress high-density lipoprotein cholesterol levels. Ann Intern Med 1992; 116:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/75\">",
"      Whitsel EA, Boyko EJ, Matsumoto AM, et al. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med 2001; 111:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/76\">",
"      Snyder PJ, Peachey H, Berlin JA, et al. Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age. Am J Med 2001; 111:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/77\">",
"      Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/78\">",
"      Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010; 95:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/79\">",
"      Brambilla DJ, O'Donnell AB, Matsumoto AM, McKinlay JB. Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men. Clin Endocrinol (Oxf) 2007; 67:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/13/4314/abstract/80\">",
"      Snyder PJ. Hypogonadism in elderly men--what to do until the evidence comes. N Engl J Med 2004; 350:440.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7457 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-4C9EBFD82E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_13_4314=[""].join("\n");
var outline_f4_13_4314=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHANGES WITH AGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Serum total testosterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Serum sex hormone-binding globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Serum free testosterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Decline in spermatogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Change in gonadotropins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CONSEQUENCES OF T DECLINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Sexual function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Bone mineral density and fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Muscle and fat mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Muscle strength",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4543601\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7730159\">",
"      Mood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cognitive function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Metabolic cardiovascular parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H356931\">",
"      IS THERE A SYNDROME OF HYPOGONADISM IN ELDERLY MEN?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TESTOSTERONE ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H252464115\">",
"      Clinical trial data",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Bone density",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Body composition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Muscle strength",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Physical function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Quality of life",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2560094\">",
"      - Mood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Potential harmful effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Erythrocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Serum lipids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H252464159\">",
"      - Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H313824889\">",
"      SUGGESTED APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H313824901\">",
"      Candidates for testosterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10044329\">",
"      Testosterone therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H611229941\">",
"      - Suggested prostate monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7457\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7457|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/47/41725\" title=\"figure 1\">",
"      Variation serum testosterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/26/21934\" title=\"figure 2\">",
"      Decreasing T with age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/61/2014\" title=\"figure 3\">",
"      Hypogonadism in aging men",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=related_link\">",
"      Causes of secondary hypogonadism in males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=related_link\">",
"      Clinical features and diagnosis of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/22/12650?source=related_link\">",
"      Endocrine changes with aging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=related_link\">",
"      Medical treatment of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=related_link\">",
"      Overview of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/45/36562?source=related_link\">",
"      Patient information: Androgen replacement in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/9/18578?source=related_link\">",
"      Patient information: Low testosterone in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=related_link\">",
"      Testosterone treatment of male hypogonadism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_13_4315="Hypertonia in infantile colic";
var content_f4_13_4315=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Features of hypertonia in infants with colic",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       The face of the baby is flushed, with occasional circumoral pallor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The abdomen is distended and tense",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The legs are drawn up on the abdomen and the feet are often cold (the legs may extend periodically during forceful cries)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The fingers are clenched",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The arms are stiff, tight, and extended (the elbows may also be flexed)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The back is arched",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Lester, BM. Colic and Excessive Crying. Report of the 105th Ross Conference on Pediatric Research, Lester, BM, Barr, RG (Eds), Ross Products Division, Columbus, OH, 1997. p. 18.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_13_4315=[""].join("\n");
var outline_f4_13_4315=null;
var title_f4_13_4316="ARA criteria for RA";
var content_f4_13_4316=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F71659&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F71659&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    1987 American College of Rheumatology (formerly American Rheumatism Association) revised classification criteria for rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Criterion",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Morning stiffness",
"       </td>",
"       <td>",
"        Morning stiffness in and around the joints, lasting at least one hour before maximal improvement.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arthritis of 3 or more joint areas",
"       </td>",
"       <td>",
"        At least 3 joint areas (out of 14 possible areas; right or left PIP, MCP, wrist, elbow, knee, ankle, MTP joints) simultaneously have had soft- tissue swelling or fluid (not bony overgrowth alone) as observed by a physician.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arthritis of hand joints",
"       </td>",
"       <td>",
"        At least one area swollen (as defined above) in a wrist, MCP, or PIP joint.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symmetric arthritis",
"       </td>",
"       <td>",
"        Simultaneous involvement of the same joint areas (as defined above) on both sides of the body (bilateral involvement of PIPs, MCPs, or MTPs, without absolute symmetry is acceptable).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rheumatoid nodules",
"       </td>",
"       <td>",
"        Subcutaneous nodules over bony prominences or extensor surfaces, or in juxta-articular regions as observed by a physician.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum rheumatoid factor",
"       </td>",
"       <td>",
"        Demonstration of abnormal amounts of serum rheumatoid factor by any method for which the result has been positive in less than 5 percent of normal control subjects.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiographic changes",
"       </td>",
"       <td>",
"        Radiographic changes typical of rheumatoid arthritis on posteroanterior hand or wrist radiographs, which must include erosions or unequivocal bony decalcification localised in, or most marked adjacent to, the involved joints (osteoarthritis changes alone do not qualify).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: For classification purposes, a patient has RA if at least four of these criteria are satisfied (the first four must have been present for at least six weeks).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_13_4316=[""].join("\n");
var outline_f4_13_4316=null;
var title_f4_13_4317="Range of motion elbow";
var content_f4_13_4317=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70587%7EPEDS%2F54423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=18\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70587%7EPEDS%2F54423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=18\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Range of motion of the elbow and wrist",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Joint action",
"       </td>",
"       <td class=\"subtitle1\">",
"        Position for examination",
"       </td>",
"       <td class=\"subtitle1\">",
"        Normal range of motion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Elbow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Extension",
"       </td>",
"       <td>",
"        Shoulder at 90&deg; abduction",
"       </td>",
"       <td rowspan=\"2\">",
"        0&deg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Palm facing up",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Flexion",
"       </td>",
"       <td>",
"        Shoulder at 90&deg; abduction",
"       </td>",
"       <td rowspan=\"2\">",
"        150&deg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wrist supinated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Supination",
"       </td>",
"       <td>",
"        Elbow flexed at 90&deg; touching the iliac crest",
"       </td>",
"       <td rowspan=\"2\">",
"        90&deg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hand in neutral, perpendicular to ground",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Pronation",
"       </td>",
"       <td>",
"        Elbow flexed at 90&deg; touching the iliac crest",
"       </td>",
"       <td rowspan=\"2\">",
"        90&deg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hand in neutral, perpendicular to ground",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Wrist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Flexion",
"       </td>",
"       <td>",
"        Elbow at 0&deg;",
"       </td>",
"       <td rowspan=\"2\">",
"        90&deg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hand fully pronated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Extension",
"       </td>",
"       <td>",
"        Elbow at 0&deg;",
"       </td>",
"       <td rowspan=\"2\">",
"        70&deg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hand fully pronated",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Strength examination of the elbow",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Joint action",
"       </td>",
"       <td class=\"subtitle1\">",
"        Position and action for examination",
"       </td>",
"       <td class=\"subtitle1\">",
"        Muscles tested",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extension",
"       </td>",
"       <td>",
"        Resisted extension",
"       </td>",
"       <td>",
"        Triceps",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Flexion",
"       </td>",
"       <td>",
"        Forearm supinated - resisted flexion",
"       </td>",
"       <td>",
"        Biceps brachii",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Forearm&nbsp;neutral- resisted flexion",
"       </td>",
"       <td>",
"        Brachioradialis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Forearm &nbsp;pronated- resisted flexion",
"       </td>",
"       <td>",
"        Brachialis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Supination",
"       </td>",
"       <td>",
"        Hand in neutral, perpendicular to ground",
"       </td>",
"       <td rowspan=\"2\">",
"        Biceps, supinator",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Resisted rotation of \"palm up\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Pronation",
"       </td>",
"       <td>",
"        Hand in neutral, perpendicular to ground",
"       </td>",
"       <td rowspan=\"2\">",
"        Pronator teres, quadratus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Resisted rotation of \"palm down\"",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The shoulder is in the neutral position with the elbow flexed at 90&deg; and touching the iliac crest.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_13_4317=[""].join("\n");
var outline_f4_13_4317=null;
var title_f4_13_4318="Age sex distribution ITP";
var content_f4_13_4318=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F78231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F78231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Incidence of immune thrombocytopenia (ITP) by age and sex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 373px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Data are presented for the incidence of ITP in females and males in different age groups. The incidence of ITP is highest in children, and may be greater in boys than in girls. In adults, the incidence increases with age. The incidence in women is greater than in men at younger ages, but in adults over age 60, the incidence of men and women is the same.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      1. Data for children from: Zeller B, Rajantie J, Hedlund-Treutiger I, et al. Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease. Acta Paediatrica 2005; 94:178.",
"      <br>",
"       2. Data for adults from: Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999; 94:909.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_13_4318=[""].join("\n");
var outline_f4_13_4318=null;
var title_f4_13_4319="Y-linked inheritance--pedigree";
var content_f4_13_4319=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F69653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F69653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Example of a pedigree showing Y-linked inheritance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 311px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Y-linked. Inheritance follows that of the Y-chromosome: all males are affected. Females are not.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_13_4319=[""].join("\n");
var outline_f4_13_4319=null;
